SK285405B6 - Bicyklické heteroaromatické zlúčeniny, spôsob ichprípravy, farmaceutický prostriedok s ich obsahoma ich použitie - Google Patents

Bicyklické heteroaromatické zlúčeniny, spôsob ichprípravy, farmaceutický prostriedok s ich obsahoma ich použitie Download PDF

Info

Publication number: SK285405B6
Authority: SK; Slovakia
Prior art keywords: methyl; ethyl; amino; fluorobenzyloxy; quinazolinamine
Prior art date: 1998-01-12

Application number

SK1050-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK10502000A3 (sk

Inventor

Malcolm Clive Carter

George Stuart Cockerill

Stephen Barry Guntrip

Karen Elizabeth Lackey

Kathryn Jane Smith

Original Assignee

Glaxo Group Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-12

Filing date

1999-01-08

Publication date

2007-01-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10825153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285405(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-01-08 Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited

2001-08-06 Publication of SK10502000A3 publication Critical patent/SK10502000A3/sk

2007-01-04 Publication of SK285405B6 publication Critical patent/SK285405B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
-1 Bicyclic heteroaromatic compounds Chemical class 0.000 title claims description 138
238000004519 manufacturing process Methods 0.000 title description 4
150000001875 compounds Chemical class 0.000 claims abstract description 118
238000011282 treatment Methods 0.000 claims abstract description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
238000002360 preparation method Methods 0.000 claims abstract description 15
101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 13
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 13
206010028980 Neoplasm Diseases 0.000 claims abstract description 12
201000011510 cancer Diseases 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims abstract description 10
230000001404 mediated effect Effects 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims description 39
239000012453 solvate Substances 0.000 claims description 27
125000005843 halogen group Chemical group 0.000 claims description 17
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
125000001424 substituent group Chemical group 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 11
125000003545 alkoxy group Chemical group 0.000 claims description 11
208000035475 disorder Diseases 0.000 claims description 10
229910052736 halogen Inorganic materials 0.000 claims description 10
150000002367 halogens Chemical class 0.000 claims description 10
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 10
108060006698 EGF receptor Proteins 0.000 claims description 9
229910052801 chlorine Inorganic materials 0.000 claims description 8
239000000460 chlorine Substances 0.000 claims description 8
125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
125000002541 furyl group Chemical group 0.000 claims description 7
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 6
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 6
239000011737 fluorine Substances 0.000 claims description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
229910052794 bromium Inorganic materials 0.000 claims description 5
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 5
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 5
125000000335 thiazolyl group Chemical group 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 4
125000001153 fluoro group Chemical group F* 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 3
MNHCZHFLNIOWQH-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(F)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 MNHCZHFLNIOWQH-UHFFFAOYSA-N 0.000 claims description 3
QEHYWVNDAWPVRJ-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=CC(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 QEHYWVNDAWPVRJ-UHFFFAOYSA-N 0.000 claims description 3
RZEMPBRXCDBLDH-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=CC(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 RZEMPBRXCDBLDH-UHFFFAOYSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
206010006187 Breast cancer Diseases 0.000 claims description 2
208000026310 Breast neoplasm Diseases 0.000 claims description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
ZADGIWJEHDJLCZ-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Br)=CC=C1OCC1=CC=CC=C1 ZADGIWJEHDJLCZ-UHFFFAOYSA-N 0.000 claims description 2
NKLDCSQPJCETMA-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC=C1 NKLDCSQPJCETMA-UHFFFAOYSA-N 0.000 claims description 2
AXVKGZLOECWENV-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 AXVKGZLOECWENV-UHFFFAOYSA-N 0.000 claims description 2
NOJHSHOVOCTOHJ-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 NOJHSHOVOCTOHJ-UHFFFAOYSA-N 0.000 claims description 2
UTGTXIQFRUQSMS-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 UTGTXIQFRUQSMS-UHFFFAOYSA-N 0.000 claims description 2
GITHWNVRQPKFEJ-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1F)=CC=C1OCC1=CC=CC=C1 GITHWNVRQPKFEJ-UHFFFAOYSA-N 0.000 claims description 2
GFRIWQBALIBSCZ-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1F)=CC=C1OCC1=CC=CC=C1 GFRIWQBALIBSCZ-UHFFFAOYSA-N 0.000 claims description 2
FVRXRENVHJBKFO-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Br)=CC=C1OCC1=CC=CC(F)=C1 FVRXRENVHJBKFO-UHFFFAOYSA-N 0.000 claims description 2
QLHIYBDUQPWZAA-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 QLHIYBDUQPWZAA-UHFFFAOYSA-N 0.000 claims description 2
WIDSGQVCKXSTPB-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2N=CC3=NC=NC(NC=4C=C(F)C(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)=C1 WIDSGQVCKXSTPB-UHFFFAOYSA-N 0.000 claims description 2
YAPPGADRBQSUIE-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=1C=C(OCC=2C=C(F)C=CC=2)C(OC)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CSC(CNCCS(C)(=O)=O)=N1 YAPPGADRBQSUIE-UHFFFAOYSA-N 0.000 claims description 2
ZUPCLUORSUOTAD-UHFFFAOYSA-N 4-[2-[(3-fluorophenyl)methoxy]phenyl]-6-[4-[(2-methylsulfonylethylamino)methyl]furan-2-yl]-1h-pyrido[3,4-d]pyrimidin-4-amine Chemical compound CS(=O)(=O)CCNCC1=COC(C=2N=CC3=C(C(N=CN3)(N)C=3C(=CC=CC=3)OCC=3C=C(F)C=CC=3)C=2)=C1 ZUPCLUORSUOTAD-UHFFFAOYSA-N 0.000 claims 1
CMPYWDJZUOBIIO-UHFFFAOYSA-N 7-fluoro-n-(3-fluoro-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1F)=CC=C1OCC1=CC=CC=C1 CMPYWDJZUOBIIO-UHFFFAOYSA-N 0.000 claims 1
YOHWLAPRGKJAEL-UHFFFAOYSA-N 7-fluoro-n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(C(=CC1=NC=N2)F)=CC1=C2NC(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 YOHWLAPRGKJAEL-UHFFFAOYSA-N 0.000 claims 1
206010005003 Bladder cancer Diseases 0.000 claims 1
HMWAXNWFVBPMKK-UHFFFAOYSA-N CCNCC1=NC(=CS1)C2=NC=C3C(=C2)C(=NC=N3)NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl Chemical compound CCNCC1=NC(=CS1)C2=NC=C3C(=C2)C(=NC=N3)NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl HMWAXNWFVBPMKK-UHFFFAOYSA-N 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
MNNXRVSQOABRRP-UHFFFAOYSA-N N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-4-thiazolyl]-4-quinazolinamine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 MNNXRVSQOABRRP-UHFFFAOYSA-N 0.000 claims 1
208000005718 Stomach Neoplasms Diseases 0.000 claims 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
206010017758 gastric cancer Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
HQHSVSSDBPWQBD-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2N=CC3=NC=NC(NC=4C=C(Br)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)=C1 HQHSVSSDBPWQBD-UHFFFAOYSA-N 0.000 claims 1
LPHALCCJJMLFMZ-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2N=CC3=NC=NC(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)=C1 LPHALCCJJMLFMZ-UHFFFAOYSA-N 0.000 claims 1
WVPMKVVGRCIEBV-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-3-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC(C=2C=C3C(NC=4C=C(Cl)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 WVPMKVVGRCIEBV-UHFFFAOYSA-N 0.000 claims 1
INOHEVIDYKGWNH-UHFFFAOYSA-N n-(3-chloro-4-phenylmethoxyphenyl)-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 INOHEVIDYKGWNH-UHFFFAOYSA-N 0.000 claims 1
RPBYFFUZCIDSBL-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2N=CC3=NC=NC(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)=C1 RPBYFFUZCIDSBL-UHFFFAOYSA-N 0.000 claims 1
IVNDWQOKRSEWBH-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(Br)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 IVNDWQOKRSEWBH-UHFFFAOYSA-N 0.000 claims 1
OKOQGGNYPJNMTO-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Br)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 OKOQGGNYPJNMTO-UHFFFAOYSA-N 0.000 claims 1
UODLBPXYHJNREK-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Br)=CC=C1OCC1=CC=CC(F)=C1 UODLBPXYHJNREK-UHFFFAOYSA-N 0.000 claims 1
QKXNWCXDCUQVGR-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 QKXNWCXDCUQVGR-UHFFFAOYSA-N 0.000 claims 1
HNCNTMHPAYQWSL-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoro-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(Cl)C(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)F)=C1 HNCNTMHPAYQWSL-UHFFFAOYSA-N 0.000 claims 1
LNFFTZLZPLIOIX-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 LNFFTZLZPLIOIX-UHFFFAOYSA-N 0.000 claims 1
KOUKAMXSEWAFHF-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 KOUKAMXSEWAFHF-UHFFFAOYSA-N 0.000 claims 1
CJGPKVRBUPRPTR-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=1C=C(OCC=2C=C(F)C=CC=2)C(OC)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(CNCCS(C)(=O)=O)O1 CJGPKVRBUPRPTR-UHFFFAOYSA-N 0.000 claims 1
CAORRJWMBDQDQW-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-5-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 CAORRJWMBDQDQW-UHFFFAOYSA-N 0.000 claims 1
IZSWEZTZKROPAX-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-5-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC=C1C1=CC=C(N=CN=C2NC=3C=CC(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 IZSWEZTZKROPAX-UHFFFAOYSA-N 0.000 claims 1
FLWJDTAEWRNVFU-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[4-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound CS(=O)(=O)CCNCC1=CSC(C=2N=CC3=NC=NC(NC=4C=CC(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)=N1 FLWJDTAEWRNVFU-UHFFFAOYSA-N 0.000 claims 1
MJIYTTGQKXMTKS-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[4-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-2-yl]quinazolin-4-amine Chemical compound CS(=O)(=O)CCNCC1=CSC(C=2C=C3C(NC=4C=CC(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=N1 MJIYTTGQKXMTKS-UHFFFAOYSA-N 0.000 claims 1
BOKWTLKKZRQINZ-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=CN=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 BOKWTLKKZRQINZ-UHFFFAOYSA-N 0.000 claims 1
208000000649 small cell carcinoma Diseases 0.000 claims 1
201000011549 stomach cancer Diseases 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
201000005112 urinary bladder cancer Diseases 0.000 claims 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract description 16
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract description 16
230000000694 effects Effects 0.000 abstract description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
238000000034 method Methods 0.000 description 49
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 42
239000000203 mixture Substances 0.000 description 42
238000006243 chemical reaction Methods 0.000 description 40
239000000047 product Substances 0.000 description 34
239000000243 solution Substances 0.000 description 33
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
239000002904 solvent Substances 0.000 description 25
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 23
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
239000007787 solid Substances 0.000 description 21
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
239000011541 reaction mixture Substances 0.000 description 19
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
210000004027 cell Anatomy 0.000 description 18
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 13
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
150000001412 amines Chemical class 0.000 description 12
239000003153 chemical reaction reagent Substances 0.000 description 12
125000004122 cyclic group Chemical group 0.000 description 11
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
239000002585 base Substances 0.000 description 10
239000000126 substance Substances 0.000 description 10
BDAIUOPDSRAOKI-UHFFFAOYSA-N 4-chloro-6-iodoquinazoline Chemical compound C1=C(I)C=C2C(Cl)=NC=NC2=C1 BDAIUOPDSRAOKI-UHFFFAOYSA-N 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000010992 reflux Methods 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
229910052799 carbon Inorganic materials 0.000 description 8
238000004440 column chromatography Methods 0.000 description 8
238000007429 general method Methods 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 7
239000003921 oil Substances 0.000 description 7
230000026731 phosphorylation Effects 0.000 description 7
229910000029 sodium carbonate Inorganic materials 0.000 description 7
239000000758 substrate Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
IPEMCIBPDYCJLO-UHFFFAOYSA-N 5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-n-(2,4,6-trimethoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC(OC)=CC(OC)=C1NC(=O)C(O1)=CC=C1CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C IPEMCIBPDYCJLO-UHFFFAOYSA-N 0.000 description 6
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000007792 addition Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000000543 intermediate Substances 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
238000006366 phosphorylation reaction Methods 0.000 description 6
230000008569 process Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
SDNXQWUJWNTDCC-UHFFFAOYSA-N 2-methylsulfonylethanamine Chemical compound CS(=O)(=O)CCN SDNXQWUJWNTDCC-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000001721 carbon Chemical group 0.000 description 5
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
239000000843 powder Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
125000004277 1,3-dioxalan-2-yl group Chemical group [H]C1([H])OC([H])(*)OC1([H])[H] 0.000 description 4
NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
101100268066 Mus musculus Zap70 gene Proteins 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
101150093908 PDGFRB gene Proteins 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
150000001299 aldehydes Chemical class 0.000 description 4
125000002619 bicyclic group Chemical group 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000006071 cream Substances 0.000 description 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000463 material Substances 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000012299 nitrogen atmosphere Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000012265 solid product Substances 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
229910052720 vanadium Inorganic materials 0.000 description 4
LMKDKHDGVBPEKI-UHFFFAOYSA-N 4-[(3-fluorophenyl)methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC(F)=C1 LMKDKHDGVBPEKI-UHFFFAOYSA-N 0.000 description 3
101100481408 Danio rerio tie2 gene Proteins 0.000 description 3
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
101100481410 Mus musculus Tek gene Proteins 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
102000001332 SRC Human genes 0.000 description 3
108060006706 SRC Proteins 0.000 description 3
125000005219 aminonitrile group Chemical group 0.000 description 3
150000001448 anilines Chemical class 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
238000000967 suction filtration Methods 0.000 description 3
150000003556 thioamides Chemical class 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
229910052727 yttrium Inorganic materials 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical compound NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 description 2
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
WQFNPHMSIVIAMP-UHFFFAOYSA-N 2-amino-4-fluoro-5-iodobenzoic acid Chemical compound NC1=CC(F)=C(I)C=C1C(O)=O WQFNPHMSIVIAMP-UHFFFAOYSA-N 0.000 description 2
LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
CKPNVNAKQGYUSK-UHFFFAOYSA-N 4,6-dichloropyrido[3,4-d]pyrimidine Chemical compound N1=CN=C2C=NC(Cl)=CC2=C1Cl CKPNVNAKQGYUSK-UHFFFAOYSA-N 0.000 description 2
AOGRSEYOPSZLKA-UHFFFAOYSA-N 6-chloro-n-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(Cl)=NC=C4N=CN=3)=CC=2)=C1 AOGRSEYOPSZLKA-UHFFFAOYSA-N 0.000 description 2
TVJBEIIXNWTFCS-UHFFFAOYSA-N 7-fluoro-6-iodo-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=C1C=C(F)C(I)=C2 TVJBEIIXNWTFCS-UHFFFAOYSA-N 0.000 description 2
QXBDUGGENUWAME-UHFFFAOYSA-N 7-fluoro-6-iodo-1h-quinazolin-4-one Chemical compound FC1=C(I)C=C2C(O)=NC=NC2=C1 QXBDUGGENUWAME-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
229920003189 Nylon 4,6 Polymers 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
230000007815 allergy Effects 0.000 description 2
229950003476 aminothiazole Drugs 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
239000011324 bead Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
QAWTYRYXDYHQNU-UHFFFAOYSA-N diazathiane Chemical compound NSN QAWTYRYXDYHQNU-UHFFFAOYSA-N 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
125000001207 fluorophenyl group Chemical group 0.000 description 2
239000006260 foam Substances 0.000 description 2
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
150000004678 hydrides Chemical class 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
208000037841 lung tumor Diseases 0.000 description 2
210000005075 mammary gland Anatomy 0.000 description 2
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 2
229960000907 methylthioninium chloride Drugs 0.000 description 2
LCEDQNDDFOCWGG-UHFFFAOYSA-N morpholine-4-carbaldehyde Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 2
DNHCEIAFWBGYFK-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 DNHCEIAFWBGYFK-UHFFFAOYSA-N 0.000 description 2
SYIHFQXGODCROG-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-iodoquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(I)=CC=C4N=CN=3)=CC=2)F)=C1 SYIHFQXGODCROG-UHFFFAOYSA-N 0.000 description 2
IXZDEQLKJAKIKK-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-iodoquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(I)=CC=C4N=CN=3)=CC=2)=C1 IXZDEQLKJAKIKK-UHFFFAOYSA-N 0.000 description 2
230000017095 negative regulation of cell growth Effects 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
239000007800 oxidant agent Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
150000008518 pyridopyrimidines Chemical class 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
238000006268 reductive amination reaction Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
PFXVKGGZWQQTSE-UHFFFAOYSA-N sulfuryl dicyanide Chemical compound N#CS(=O)(=O)C#N PFXVKGGZWQQTSE-UHFFFAOYSA-N 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
LGPVTNAJFDUWLF-UHFFFAOYSA-N 2-amino-4-fluorobenzoic acid Chemical compound NC1=CC(F)=CC=C1C(O)=O LGPVTNAJFDUWLF-UHFFFAOYSA-N 0.000 description 1
MNQVIZWWCRPZOK-UHFFFAOYSA-N 2-bromo-1,3-thiazole-4-carbaldehyde Chemical compound BrC1=NC(C=O)=CS1 MNQVIZWWCRPZOK-UHFFFAOYSA-N 0.000 description 1
UROSHBSDTBPGPU-UHFFFAOYSA-N 2-bromo-4-(1,3-dioxolan-2-yl)-1,3-thiazole Chemical compound S1C(Br)=NC(C2OCCO2)=C1 UROSHBSDTBPGPU-UHFFFAOYSA-N 0.000 description 1
CYWGSFFHHMQKET-UHFFFAOYSA-N 2-methylsulfanylethanamine Chemical compound CSCCN CYWGSFFHHMQKET-UHFFFAOYSA-N 0.000 description 1
QGKGASXQTBQINX-UHFFFAOYSA-N 3,4-dihydro-1h-pyrimidin-2-one Chemical compound O=C1NCC=CN1 QGKGASXQTBQINX-UHFFFAOYSA-N 0.000 description 1
125000006279 3-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Br)=C1[H])C([H])([H])* 0.000 description 1
XFGRSRQUIAXQNB-UHFFFAOYSA-N 3-chloro-4-[(2-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC=C1F XFGRSRQUIAXQNB-UHFFFAOYSA-N 0.000 description 1
VQCZIZIHGIJMII-UHFFFAOYSA-N 3-chloro-4-[(4-fluorophenyl)methoxy]aniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=C(F)C=C1 VQCZIZIHGIJMII-UHFFFAOYSA-N 0.000 description 1
DKTRZBWXGOPYIX-UHFFFAOYSA-N 3-chloro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(Cl)=C1 DKTRZBWXGOPYIX-UHFFFAOYSA-N 0.000 description 1
WOWKZTBVWKKGJV-UHFFFAOYSA-N 3-chloro-4-phenylmethoxyaniline Chemical compound ClC1=CC(N)=CC=C1OCC1=CC=CC=C1 WOWKZTBVWKKGJV-UHFFFAOYSA-N 0.000 description 1
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
XLEYXHRMSUPJST-UHFFFAOYSA-N 3-fluoro-4-phenylmethoxyaniline Chemical compound FC1=CC(N)=CC=C1OCC1=CC=CC=C1 XLEYXHRMSUPJST-UHFFFAOYSA-N 0.000 description 1
FVUMUZSSIVMHEQ-UHFFFAOYSA-N 4-(1-benzylindazol-5-yl)-6-iodo-1h-quinazolin-4-amine Chemical compound N1C=NC2=CC=C(I)C=C2C1(N)C(C=C1C=N2)=CC=C1N2CC1=CC=CC=C1 FVUMUZSSIVMHEQ-UHFFFAOYSA-N 0.000 description 1
ARKQSUYCILKUKZ-UHFFFAOYSA-N 4-[(2-fluorophenyl)methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC=C1F ARKQSUYCILKUKZ-UHFFFAOYSA-N 0.000 description 1
URUXBDVSGYSTGN-UHFFFAOYSA-N 4-[(3-bromophenyl)methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC(Br)=C1 URUXBDVSGYSTGN-UHFFFAOYSA-N 0.000 description 1
WKJLZHPOOMPGPI-UHFFFAOYSA-N 4-[(4-fluorophenyl)methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=C(F)C=C1 WKJLZHPOOMPGPI-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
KSVWUYLDKMOEDI-UHFFFAOYSA-N 4-[[3-(trifluoromethyl)phenyl]methoxy]aniline Chemical compound C1=CC(N)=CC=C1OCC1=CC=CC(C(F)(F)F)=C1 KSVWUYLDKMOEDI-UHFFFAOYSA-N 0.000 description 1
HCKJWAIVDILSFO-UHFFFAOYSA-N 4-chloro-7-fluoro-6-iodoquinazoline;hydrochloride Chemical compound Cl.C1=NC(Cl)=C2C=C(I)C(F)=CC2=N1 HCKJWAIVDILSFO-UHFFFAOYSA-N 0.000 description 1
PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical group ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical compound ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
SWNXZUKRZWHDGZ-UHFFFAOYSA-N 4-tributylstannyl-1,3-thiazole-2-carbaldehyde Chemical compound CCCC[Sn](CCCC)(CCCC)C1=CSC(C=O)=N1 SWNXZUKRZWHDGZ-UHFFFAOYSA-N 0.000 description 1
SMDGIJITNLOLSD-UHFFFAOYSA-N 5-[2-(3-bromo-4-phenylmethoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Br)=CC=1NC(N=C1C=N2)=NC=C1C=C2C1=CC=C(C=O)O1 SMDGIJITNLOLSD-UHFFFAOYSA-N 0.000 description 1
FGBNTBAYARRIFX-UHFFFAOYSA-N 5-[2-(3-chloro-4-phenylmethoxyanilino)pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Cl)=CC=1NC(N=C1C=N2)=NC=C1C=C2C1=CC=C(C=O)O1 FGBNTBAYARRIFX-UHFFFAOYSA-N 0.000 description 1
YNPIJTZJPIIXEI-UHFFFAOYSA-N 5-[2-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3N=C4C=NC(=CC4=CN=3)C=3OC(C=O)=CC=3)=CC=2)Cl)=C1 YNPIJTZJPIIXEI-UHFFFAOYSA-N 0.000 description 1
NGZKIKQCAUGQCK-UHFFFAOYSA-N 5-[2-[3-fluoro-4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC=1C=C(COC2=C(C=C(C=C2)NC=2N=CC3=C(N=2)C=NC(=C3)C2=CC=C(O2)C=O)F)C=CC=1 NGZKIKQCAUGQCK-UHFFFAOYSA-N 0.000 description 1
SPYDUPKZAXEXRA-UHFFFAOYSA-N 5-[4-(3-chloro-4-phenylmethoxyanilino)-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=12C=C(C=3OC(C=O)=CC=3)C(F)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 SPYDUPKZAXEXRA-UHFFFAOYSA-N 0.000 description 1
FSQQOQJTZOTQMX-UHFFFAOYSA-N 5-[4-(3-chloro-4-phenylmethoxyanilino)quinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(Cl)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(C=O)O1 FSQQOQJTZOTQMX-UHFFFAOYSA-N 0.000 description 1
NPKSKAFUBBUMDT-UHFFFAOYSA-N 5-[4-(3-fluoro-4-phenylmethoxyanilino)quinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=CC=CC=2)C(F)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(C=O)O1 NPKSKAFUBBUMDT-UHFFFAOYSA-N 0.000 description 1
LRRYDADCSUDXKL-UHFFFAOYSA-N 5-[4-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(=CC=2)C=2C3=CC(=C(F)C=C3N=CN=2)C=2OC(C=O)=CC=2)Br)=C1 LRRYDADCSUDXKL-UHFFFAOYSA-N 0.000 description 1
XQPZOUAAXRXPAM-UHFFFAOYSA-N 5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)Cl)=C1 XQPZOUAAXRXPAM-UHFFFAOYSA-N 0.000 description 1
DEECATMLEICPKT-UHFFFAOYSA-N 5-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoroquinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(=CC=2)C=2C3=CC(=C(F)C=C3N=CN=2)C=2OC(C=O)=CC=2)Cl)=C1 DEECATMLEICPKT-UHFFFAOYSA-N 0.000 description 1
ASQPKYWSIJSYSQ-UHFFFAOYSA-N 5-[4-[3-fluoro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)F)=C1 ASQPKYWSIJSYSQ-UHFFFAOYSA-N 0.000 description 1
PGQXNMBXXLJOMX-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]-3-methoxyanilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound C=1C=C(OCC=2C=C(F)C=CC=2)C(OC)=CC=1NC(C1=C2)=NC=NC1=CC=C2C1=CC=C(C=O)O1 PGQXNMBXXLJOMX-UHFFFAOYSA-N 0.000 description 1
LTCHCGGNDRFIMA-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)=C1 LTCHCGGNDRFIMA-UHFFFAOYSA-N 0.000 description 1
XYTSDPWYAUQDNM-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]anilino]pyrido[3,4-d]pyrimidin-6-yl]furan-3-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC=C(C=O)C=3)=CC=2)=C1 XYTSDPWYAUQDNM-UHFFFAOYSA-N 0.000 description 1
DXNXDDHUDHVDEO-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=CC=C4N=CN=3)C=3OC(C=O)=CC=3)=CC=2)=C1 DXNXDDHUDHVDEO-UHFFFAOYSA-N 0.000 description 1
GVZIVDUUBRKFLP-UHFFFAOYSA-N 5-[4-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C=CC(=CC=2)C=2C3=CC(=NC=C3N=CN=2)C=2OC(C=O)=CC=2)=C1 GVZIVDUUBRKFLP-UHFFFAOYSA-N 0.000 description 1
YGJKWLDPSHEURC-UHFFFAOYSA-N 5-[7-fluoro-4-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]quinazolin-6-yl]furan-2-carbaldehyde Chemical compound FC1=CC=CC(COC=2C(=CC(=CC=2)C=2C3=CC(=C(F)C=C3N=CN=2)C=2OC(C=O)=CC=2)F)=C1 YGJKWLDPSHEURC-UHFFFAOYSA-N 0.000 description 1
UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 1
OHHIZVCDNOKAMJ-UHFFFAOYSA-N 6-[5-(1,3-dioxolan-2-yl)furan-2-yl]-n-[4-[(3-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound FC1=CC=CC(COC=2C=CC(NC=3C4=CC(=NC=C4N=CN=3)C=3OC(=CC=3)C3OCCO3)=CC=2)=C1 OHHIZVCDNOKAMJ-UHFFFAOYSA-N 0.000 description 1
JFJNDMNYNYLFLJ-UHFFFAOYSA-N 6-bromo-4-chloroquinazoline Chemical compound C1=C(Br)C=C2C(Cl)=NC=NC2=C1 JFJNDMNYNYLFLJ-UHFFFAOYSA-N 0.000 description 1
BBPUOYYUBFLNML-UHFFFAOYSA-N 6-chloro-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1C=NC(Cl)=C2 BBPUOYYUBFLNML-UHFFFAOYSA-N 0.000 description 1
BQZAKZHHKHKXOR-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(3-fluoro-4-phenylmethoxyphenyl)quinazolin-4-amine Chemical compound FC1=CC(NC=2C3=CC(Cl)=C(F)C=C3N=CN=2)=CC=C1OCC1=CC=CC=C1 BQZAKZHHKHKXOR-UHFFFAOYSA-N 0.000 description 1
WELMWKSCIDCGPR-UHFFFAOYSA-N 6-chloro-n-(3-chloro-4-phenylmethoxyphenyl)-7-fluoroquinazolin-4-amine Chemical compound C=12C=C(Cl)C(F)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=C1 WELMWKSCIDCGPR-UHFFFAOYSA-N 0.000 description 1
RSHUMBXTLYMGNO-UHFFFAOYSA-N 6-chloro-n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(Cl)=C(F)C=C4N=CN=3)=CC=2)Cl)=C1 RSHUMBXTLYMGNO-UHFFFAOYSA-N 0.000 description 1
AEBLZKFVJJBECZ-UHFFFAOYSA-N 6-chloro-n-[4-[(4-fluorophenyl)methoxy]phenyl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound C1=CC(F)=CC=C1COC(C=C1)=CC=C1NC1=NC=NC2=CN=C(Cl)C=C12 AEBLZKFVJJBECZ-UHFFFAOYSA-N 0.000 description 1
CFOQGEZWGSBPAJ-UHFFFAOYSA-N 6-iodo-n-[4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl]quinazolin-4-amine Chemical compound FC(F)(F)C1=CC=CC(COC=2C=CC(NC=3C4=CC(I)=CC=C4N=CN=3)=CC=2)=C1 CFOQGEZWGSBPAJ-UHFFFAOYSA-N 0.000 description 1
HRAXMJGGCFDZBT-UHFFFAOYSA-N 7-fluoro-n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=C3C=2)F)=C1 HRAXMJGGCFDZBT-UHFFFAOYSA-N 0.000 description 1
GUXDRWBSRNGGPZ-UHFFFAOYSA-N 7-fluoro-n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C(=CC3=NC=NC(NC=4C=C(F)C(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)F)=C1 GUXDRWBSRNGGPZ-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
BHDCZIDHZDRBHI-UHFFFAOYSA-N C1=CC=C(C=C1)COC2=C(C=C(C=C2)C3=NC=NC4=CC(=C(C=C43)C5=CC=C(O5)C=O)F)F Chemical compound C1=CC=C(C=C1)COC2=C(C=C(C=C2)C3=NC=NC4=CC(=C(C=C43)C5=CC=C(O5)C=O)F)F BHDCZIDHZDRBHI-UHFFFAOYSA-N 0.000 description 1
DCGZMZNRBKVKTF-UHFFFAOYSA-N C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)I)C(F)(F)F Chemical compound C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)I)C(F)(F)F DCGZMZNRBKVKTF-UHFFFAOYSA-N 0.000 description 1
BPWCFJBULGVJDI-UHFFFAOYSA-N C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)I)F Chemical compound C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=C3C=C(C=C4)I)F BPWCFJBULGVJDI-UHFFFAOYSA-N 0.000 description 1
OHSPABAIGVISEU-UHFFFAOYSA-N C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=CN=C(C=C43)Cl)C(F)(F)F Chemical compound C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=CN=C(C=C43)Cl)C(F)(F)F OHSPABAIGVISEU-UHFFFAOYSA-N 0.000 description 1
FXEAXYFDCLFFRN-UHFFFAOYSA-N C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=CN=C(C=C43)Cl)Cl Chemical compound C1=CC=C(C=C1)COC2=C(C=C(C=C2)NC3=NC=NC4=CN=C(C=C43)Cl)Cl FXEAXYFDCLFFRN-UHFFFAOYSA-N 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010061968 Gastric neoplasm Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
239000007993 MOPS buffer Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
108091008606 PDGF receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000012979 RPMI medium Substances 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
239000003637 basic solution Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
PPDJNZTUDFPAHX-UHFFFAOYSA-N benzyltrimethylammonium dichloroiodate Chemical compound Cl[I-]Cl.C[N+](C)(C)CC1=CC=CC=C1 PPDJNZTUDFPAHX-UHFFFAOYSA-N 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
125000000068 chlorophenyl group Chemical group 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical group C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
229960004126 codeine Drugs 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
RFMQOHXWHFHOJF-UHFFFAOYSA-N cyano thiocyanate Chemical compound N#CSC#N RFMQOHXWHFHOJF-UHFFFAOYSA-N 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
125000005879 dioxolanyl group Chemical group 0.000 description 1
GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
239000012259 ether extract Substances 0.000 description 1
ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000007789 gas Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
150000002390 heteroarenes Chemical class 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
150000002391 heterocyclic compounds Chemical class 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
239000005457 ice water Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000012452 mother liquor Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
RRURVOSFXQLYQR-UHFFFAOYSA-N n-(3-bromo-4-phenylmethoxyphenyl)-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Br)C(OCC=4C=CC=CC=4)=CC=3)C2=C1 RRURVOSFXQLYQR-UHFFFAOYSA-N 0.000 description 1
RRONZTYLARBRBH-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1 RRONZTYLARBRBH-UHFFFAOYSA-N 0.000 description 1
RPJDOKPJFVVEHP-UHFFFAOYSA-N n-(3-fluoro-4-phenylmethoxyphenyl)-6-[2-[(2-methylsulfonylethylamino)methyl]furan-3-yl]quinazolin-4-amine Chemical compound O1C=CC(C=2C=C3C(NC=4C=C(F)C(OCC=5C=CC=CC=5)=CC=4)=NC=NC3=CC=2)=C1CNCCS(=O)(=O)C RPJDOKPJFVVEHP-UHFFFAOYSA-N 0.000 description 1
LPCDFUQIFYVPHL-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(Cl)=C(F)C=C4N=CN=3)=CC=2)Br)=C1 LPCDFUQIFYVPHL-UHFFFAOYSA-N 0.000 description 1
LFTWTVCYYTWYNU-UHFFFAOYSA-N n-[3-bromo-4-[(3-fluorophenyl)methoxy]phenyl]-6-chloropyrido[3,4-d]pyrimidin-4-amine Chemical compound FC1=CC=CC(COC=2C(=CC(NC=3C4=CC(Cl)=NC=C4N=CN=3)=CC=2)Br)=C1 LFTWTVCYYTWYNU-UHFFFAOYSA-N 0.000 description 1
XURMGEAAVZEGOJ-UHFFFAOYSA-N n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3N=C(CNCCS(C)(=O)=O)SC=3)C(OC)=CC2=NC=NC=1NC(C=C1Cl)=CC=C1OCC1=CC=CC(F)=C1 XURMGEAAVZEGOJ-UHFFFAOYSA-N 0.000 description 1
DXPUMHHTGDHAKK-UHFFFAOYSA-N n-[3-fluoro-4-[(3-fluorophenyl)methoxy]phenyl]-7-methoxy-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound C=12C=C(C=3OC(CNCCS(C)(=O)=O)=CC=3)C(OC)=CC2=NC=NC=1NC(C=C1F)=CC=C1OCC1=CC=CC(F)=C1 DXPUMHHTGDHAKK-UHFFFAOYSA-N 0.000 description 1
MTNSKHGTKRLTGC-UHFFFAOYSA-N n-[4-[(3-bromophenyl)methoxy]phenyl]-6-iodoquinazolin-4-amine Chemical compound BrC1=CC=CC(COC=2C=CC(NC=3C4=CC(I)=CC=C4N=CN=3)=CC=2)=C1 MTNSKHGTKRLTGC-UHFFFAOYSA-N 0.000 description 1
GXGWOCHDVVBGCV-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]-3-methoxyphenyl]-6-iodoquinazolin-4-amine Chemical compound COC1=CC(NC=2C3=CC(I)=CC=C3N=CN=2)=CC=C1OCC1=CC=CC(F)=C1 GXGWOCHDVVBGCV-UHFFFAOYSA-N 0.000 description 1
LAKWJGJDTGUFQF-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[2-[(2-methylsulfonylethylamino)methyl]-1,3-thiazol-4-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound S1C(CNCCS(=O)(=O)C)=NC(C=2N=CC3=NC=NC(NC=4C=CC(OCC=5C=C(F)C=CC=5)=CC=4)=C3C=2)=C1 LAKWJGJDTGUFQF-UHFFFAOYSA-N 0.000 description 1
FFYLLKGJBBUFGL-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[4-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine Chemical compound CS(=O)(=O)CCNCC1=COC(C=2C=C3C(NC=4C=CC(OCC=5C=C(F)C=CC=5)=CC=4)=NC=NC3=CC=2)=C1 FFYLLKGJBBUFGL-UHFFFAOYSA-N 0.000 description 1
UBVRRYAQHZDQPH-UHFFFAOYSA-N n-[4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1)=CC=C1OCC1=CC=CC(F)=C1 UBVRRYAQHZDQPH-UHFFFAOYSA-N 0.000 description 1
GVQOYYNXZCOMAL-UHFFFAOYSA-N n-[4-[(4-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]pyrido[3,4-d]pyrimidin-4-amine Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C(N=CC1=NC=N2)=CC1=C2NC(C=C1)=CC=C1OCC1=CC=C(F)C=C1 GVQOYYNXZCOMAL-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000001451 organic peroxides Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
229910000080 stannane Inorganic materials 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
150000003557 thiazoles Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
WARKYKQCOXTIAO-UHFFFAOYSA-N tributyl(2-ethoxyethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C/OCC WARKYKQCOXTIAO-UHFFFAOYSA-N 0.000 description 1
125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)
Hydrogenated Pyridines (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SK1050-2000A 1998-01-12 1999-01-08 Bicyklické heteroaromatické zlúčeniny, spôsob ichprípravy, farmaceutický prostriedok s ich obsahoma ich použitie SK285405B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9800569.7A GB9800569D0 (en)	1998-01-12	1998-01-12	Heterocyclic compounds
PCT/EP1999/000048 WO1999035146A1 (en)	1998-01-12	1999-01-08	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Publications (2)

Publication Number	Publication Date
SK10502000A3 SK10502000A3 (sk)	2001-08-06
SK285405B6 true SK285405B6 (sk)	2007-01-04

Family

ID=10825153

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1050-2000A SK285405B6 (sk)	1998-01-12	1999-01-08	Bicyklické heteroaromatické zlúčeniny, spôsob ichprípravy, farmaceutický prostriedok s ich obsahoma ich použitie

Country Status (47)

Country	Link
US (11)	US6727256B1 (is)
EP (3)	EP1047694B1 (is)
JP (2)	JP3390741B2 (is)
KR (1)	KR100569776B1 (is)
CN (1)	CN1134438C (is)
AP (1)	AP1446A (is)
AR (2)	AR015507A1 (is)
AT (3)	ATE270670T1 (is)
AU (2)	AU749549C (is)
BG (1)	BG64825B1 (is)
BR (1)	BR9906904B1 (is)
CA (1)	CA2317589C (is)
CO (1)	CO4820390A1 (is)
CY (3)	CY1105618T1 (is)
CZ (1)	CZ298047B6 (is)
DE (4)	DE122008000048I1 (is)
DK (3)	DK1047694T3 (is)
EA (1)	EA002455B1 (is)
EE (1)	EE04616B1 (is)
EG (1)	EG24743A (is)
ES (3)	ES2262087T3 (is)
FR (1)	FR08C0038I2 (is)
GB (1)	GB9800569D0 (is)
GE (1)	GEP20022678B (is)
HR (2)	HRP20000469B1 (is)
HU (1)	HU227593B1 (is)
IL (2)	IL137041A0 (is)
IS (1)	IS2276B (is)
LU (1)	LU91475I2 (is)
MA (1)	MA26596A1 (is)
ME (1)	ME00757B (is)
MY (1)	MY124055A (is)
NL (1)	NL300360I2 (is)
NO (2)	NO316176B1 (is)
NZ (1)	NZ505456A (is)
OA (1)	OA11444A (is)
PE (1)	PE20000230A1 (is)
PL (1)	PL192746B1 (is)
PT (3)	PT1454907E (is)
RS (1)	RS49779B (is)
SI (3)	SI1460072T1 (is)
SK (1)	SK285405B6 (is)
TR (1)	TR200002015T2 (is)
TW (1)	TW477788B (is)
UA (1)	UA66827C2 (is)
WO (1)	WO1999035146A1 (is)
ZA (1)	ZA99172B (is)

Families Citing this family (442)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6294532B1 (en)	1997-08-22	2001-09-25	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
RS49779B (sr) *	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
HK1039126B (en)	1998-10-08	2005-09-30	阿斯特拉曾尼卡有限公司	Quinazoline derivatives
GB2345486A (en) *	1999-01-11	2000-07-12	Glaxo Group Ltd	Heteroaromatic protein tyrosine kinase inhibitors
MXPA01008182A (es)	1999-02-10	2003-08-20	Astrazeneca Ab	Derivados de quinazolina como inhibidores de angiotensina.
GB9910579D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
GB9910580D0 (en)	1999-05-08	1999-07-07	Zeneca Ltd	Chemical compounds
MEP45508A (en)	1999-06-21	2011-02-10	Boehringer Ingelheim Pharma	Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
JP2003504363A (ja)	1999-07-09	2003-02-04	グラクソグループリミテッド	プロテインチロシンキナーゼ阻害剤としてのアニリノキナゾリン類
US6933299B1 (en)	1999-07-09	2005-08-23	Smithkline Beecham Corporation	Anilinoquinazolines as protein tyrosine kinase inhibitors
KR20020032612A (ko)	1999-09-21	2002-05-03	다비드 에 질레스	퀴나졸린 유도체 및 그의 의약으로서의 용도
UA74803C2 (uk)	1999-11-11	2006-02-15	Осі Фармасьютікалз, Інк.	Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
AU2001228638A1 (en) *	2000-01-28	2001-08-07	Astrazeneca Ab	Chemical compounds
GB0002952D0 (en) *	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
US6521618B2 (en)	2000-03-28	2003-02-18	Wyeth	3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
AR035851A1 (es) *	2000-03-28	2004-07-21	Wyeth Corp	3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
CA2409139A1 (en)	2000-05-02	2001-11-08	Array Biopharma, Inc.	Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted sulfones
JP4044839B2 (ja)	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体
RU2283311C2 (ru)	2000-06-28	2006-09-10	Астразенека Аб	Замещенные производные хиназолина и их применение в качестве ингибиторов
MXPA02012681A (es) *	2000-06-30	2003-04-25	Glaxo Group Ltd	Compuestos de sales de ditosilato de quinazolina.
EP1792902A1 (en) *	2000-06-30	2007-06-06	Glaxo Group Limited	Processes for preparation of 5-(6-quinazolinyl)-furan-2-carbaldehydes
WO2002012226A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Quinoline derivatives having vegf inhibiting activity
HUP0302221A3 (en)	2000-09-20	2004-01-28	Merck Patent Gmbh	4-amino-quinazolines
DE60134679D1 (de)	2000-10-20	2008-08-14	Eisai R&D Man Co Ltd	Stickstoff enthaltende aromatische Heterozyklen
US7776315B2 (en)	2000-10-31	2010-08-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and additional active ingredients
WO2002036570A1 (en)	2000-11-02	2002-05-10	Astrazeneca Ab	4-substituted quinolines as antitumor agents
JP2004514718A (ja)	2000-11-02	2004-05-20	アストラゼネカ　アクチボラグ	抗癌剤としての置換キノリン類
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
SV2007000775A (es)	2001-01-05	2007-03-15	Pfizer	Anticuerpos contra el receptor del factor de crecimiento similar a insulina
JP4458746B2 (ja) *	2001-01-16	2010-04-28	グラクソグループリミテッド	癌の治療方法
EP1512413A3 (en) *	2001-01-16	2009-09-23	Glaxo Group Limited	Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
AU2002252338B2 (en) *	2001-03-15	2007-09-13	Rhode Island Hospital, A Lifespan Partner	Taurine compounds
AR035792A1 (es) *	2001-03-23	2004-07-14	Bayer Corp	Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
DK1370553T3 (da) *	2001-03-23	2006-09-11	Bayer Corp	Rho-kinase-inhibitorer
ATE330956T1 (de)	2001-04-13	2006-07-15	Pfizer Prod Inc	Bizyklisch substituierte 4- aminopyridopyrimidinderivate
WO2002092578A1 (en) *	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2003000194A2 (en)	2001-06-21	2003-01-03	Pfizer Inc.	Thienopyridine and thienopyrimidine anticancer agents
US20090197852A9 (en) *	2001-08-06	2009-08-06	Johnson Robert G Jr	Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
US7829566B2 (en)	2001-09-17	2010-11-09	Werner Mederski	4-amino-quinazolines
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
AU2003202263A1 (en)	2002-01-10	2003-07-30	Bayer Healthcare Ag	Roh-kinase inhibitors
EP1471910A2 (en)	2002-01-17	2004-11-03	Neurogen Corporation	Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
WO2003062225A1 (en)	2002-01-23	2003-07-31	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives as rho-kinase inhibitors
ES2298497T3 (es)	2002-01-23	2008-05-16	Bayer Pharmaceuticals Corporation	Inhibidores de quinasa rho.
US7268230B2 (en)	2002-02-01	2007-09-11	Astrazeneca Ab	Quinazoline compounds
US20050130995A1 (en) *	2002-02-06	2005-06-16	Ube Industries, Ltd.	Process for producing 4-aminoquinazoline compound
JP2005534623A (ja) *	2002-04-08	2005-11-17	スミスクラインビーチャムコーポレーション	Ｅｒｂファミリーの阻害剤並びにｒａｆ及び／又はｒａｓ阻害剤を投与することを含む癌の治療法
DE10221018A1 (de)	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
JPWO2003101491A1 (ja) *	2002-06-03	2005-09-29	三菱ウェルファーマ株式会社	Ｈｅｒ２又は／及びＥＧＦＲ発現又は活性化対象に用いる予防又は／及び治療剤
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
US20040048887A1 (en) *	2002-07-09	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
GB0215823D0 (en)	2002-07-09	2002-08-14	Astrazeneca Ab	Quinazoline derivatives
JP2005536486A (ja)	2002-07-09	2005-12-02	アストラゼネカアクチボラグ	癌の処置に使用するためのキナゾリン誘導体
EP1521747B1 (en) *	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
GB0304367D0 (en) *	2003-02-26	2003-04-02	Pharma Mar Sau	Methods for treating psoriasis
GB0225579D0 (en)	2002-11-02	2002-12-11	Astrazeneca Ab	Chemical compounds
US8505468B2 (en) *	2002-11-19	2013-08-13	Sharp Kabushiki Kaisha	Substrate accommodating tray
TW200418480A (en) *	2002-12-13	2004-10-01	Neurogen Corp	2-substituted quinazolin-4-ylamine analogues
SI1585743T1 (sl)	2002-12-19	2007-08-31	Pfizer	Spojine 2-(1H-indazol-6-ilamino)-benzamida kot inhibitorji protein-kinaz, uporabnih pri zdravljenju očesnih bolezni
AU2003292435A1 (en) *	2002-12-23	2004-07-14	Astrazeneca Ab	4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
US20060167026A1 (en) *	2003-01-06	2006-07-27	Hiroyuki Nawa	Antipsychotic molecular-targeting epithelial growth factor receptor
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CN103265477B (zh)	2003-02-26	2017-01-11	苏根公司	作为蛋白激酶抑制剂的氨基杂芳基化合物
BRPI0410634A (pt)	2003-05-30	2006-06-13	Astrazeneca Uk Ltd	processo
TW200510373A (en)	2003-07-14	2005-03-16	Neurogen Corp	Substituted quinolin-4-ylamine analogues
US7329664B2 (en)	2003-07-16	2008-02-12	Neurogen Corporation	Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
DK1648998T3 (en)	2003-07-18	2015-01-05	Amgen Inc	Specific binding agents for hepatocyte growth factor
EP1653986A4 (en)	2003-08-01	2007-03-14	Smithkline Beecham Corp	TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
ATE412655T1 (de)	2003-08-29	2008-11-15	Pfizer	Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
GB0321066D0 (en) *	2003-09-09	2003-10-08	Pharma Mar Sau	New antitumoral compounds
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
ES2925655T3 (es) *	2003-09-26	2022-10-19	Exelixis Inc	Moduladores c-Met y métodos de uso
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
EP1682123A1 (en) *	2003-11-07	2006-07-26	SmithKline Beecham (Cork) Limited	Cancer treatment method
JP4303726B2 (ja)	2003-11-11	2009-07-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウレア誘導体およびその製造方法
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
NZ547794A (en) *	2003-12-18	2009-11-27	Janssen Pharmaceutica Nv	Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
GB0330002D0 (en)	2003-12-24	2004-01-28	Astrazeneca Ab	Quinazoline derivatives
EP1755394A4 (en) *	2004-04-16	2009-08-05	Smithkline Beecham Corp	METHOD OF TREATING CANCER
AP2204A (en)	2004-05-06	2011-02-07	Warner Lambert Co	4-phenylamino-quinazolin-6-yl-amides.
NZ551622A (en) *	2004-06-03	2010-01-29	Smithkline Beecham Cork Ltd	Treatment of esophageal cancer with lapatinib tosylate
WO2005120512A2 (en) *	2004-06-04	2005-12-22	Smithkline Beecham (Cork) Limited	Cancer treatment method
CA2569404A1 (en) *	2004-06-04	2005-12-22	Amphora Discovery Corporation	Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
JP2008504292A (ja) *	2004-06-24	2008-02-14	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	免疫増強用の化合物
US20100226931A1 (en) *	2004-06-24	2010-09-09	Nicholas Valiante	Compounds for immunopotentiation
CN101014365B (zh)	2004-07-16	2011-04-13	辉瑞产品公司	使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤
US20060035893A1 (en)	2004-08-07	2006-02-16	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PL1786785T3 (pl)	2004-08-26	2010-08-31	Pfizer	Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
ES2322175T3 (es)	2004-09-17	2009-06-17	EISAI R&D MANAGEMENT CO., LTD.	Composicion medicinal con estabilidad mejorada y gelificacion reducida.
TW200621251A (en)	2004-10-12	2006-07-01	Neurogen Corp	Substituted biaryl quinolin-4-ylamine analogues
JP2008521900A (ja)	2004-11-30	2008-06-26	アムジエン・インコーポレーテツド	キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
GB0427131D0 (en) *	2004-12-10	2005-01-12	Glaxosmithkline Biolog Sa	Novel combination
US7947676B2 (en)	2004-12-14	2011-05-24	Astrazeneca Ab	Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
RU2007119432A (ru) *	2004-12-17	2009-01-27	Смитклайн Бичам (Корк) Лимитед (Ie)	Способ лечения рака
WO2006068826A2 (en) *	2004-12-21	2006-06-29	Smithkline Beecham Corporation	2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
US7812022B2 (en) *	2004-12-21	2010-10-12	Glaxosmithkline Llc	2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
PE20060777A1 (es)	2004-12-24	2006-10-06	Boehringer Ingelheim Int	Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
JP2008526997A (ja) *	2005-01-14	2008-07-24	ニューロジェン・コーポレーション	ヘテロアリール置換キノリン−４−イルアミン類縁体
BRPI0607809A2 (pt)	2005-02-18	2009-06-13	Abraxis Bioscience Inc	uso de uma composição compreendendo nanopartìculas, composição e kit
US8735394B2 (en) *	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US20060216288A1 (en) *	2005-03-22	2006-09-28	Amgen Inc	Combinations for the treatment of cancer
WO2006105488A2 (en)	2005-03-31	2006-10-05	Agensys, Inc.	Antibodies and related molecules that bind to 161p2f10b proteins
TW200716204A (en)	2005-04-19	2007-05-01	Smithkline Beecham Cork Ltd	Pharmaceutical composition
EP2444421A1 (en)	2005-04-26	2012-04-25	Pfizer Inc.	P-Cadherin antibodies
US9006240B2 (en)	2005-08-02	2015-04-14	Eisai R&D Management Co., Ltd.	Method for assay on the effect of vascularization inhibitor
CN101517068B (zh)	2005-09-07	2017-02-08	安进弗里蒙特公司	活化素受体样激酶‑1的人单克隆抗体
WO2007034144A1 (en)	2005-09-20	2007-03-29	Astrazeneca Ab	4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
JP5055284B2 (ja)	2005-09-20	2012-10-24	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	インシュリン様成長因子−１受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
WO2007054550A1 (en)	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
US7807673B2 (en) *	2005-12-05	2010-10-05	Glaxosmithkline Llc	2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
CN101003514A (zh)	2006-01-20	2007-07-25	上海艾力斯医药科技有限公司	喹唑啉衍生物、其制备方法及用途
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
AR059066A1 (es) *	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
EP1981886B1 (en) *	2006-01-31	2009-08-12	F.Hoffmann-La Roche Ag	7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
PE20070978A1 (es) *	2006-02-14	2007-11-15	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
TW200808739A (en) *	2006-04-06	2008-02-16	Novartis Vaccines & Diagnostic	Quinazolines for PDK1 inhibition
US20090203718A1 (en) *	2006-04-13	2009-08-13	Smithkline Beecham (Cork) Ltd.	Cancer treatment method
EP2010521A1 (en)	2006-04-19	2009-01-07	Novartis Ag	Indazole compounds and methods for inhibition of cdc7
MX2008013990A (es)	2006-05-09	2009-01-29	Pfizer Prod Inc	Derivados de cicloalquilamino acidos.
NL2000613C2 (nl)	2006-05-11	2007-11-20	Pfizer Prod Inc	Triazoolpyrazinederivaten.
CA2652442C (en)	2006-05-18	2014-12-09	Eisai R & D Management Co., Ltd.	Antitumor agent for thyroid cancer
DE602006004196D1 (de) *	2006-06-01	2009-01-22	Cellzome Ag	Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung
EP2032989B2 (en)	2006-06-30	2015-10-28	Merck Sharp & Dohme Corp.	Igfbp2 biomarker
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20121506A1 (es)	2006-07-14	2012-11-26	Amgen Inc	Compuestos triazolopiridinas como inhibidores de c-met
WO2008024439A2 (en)	2006-08-22	2008-02-28	Concert Pharmaceuticals Inc.	4-aminoquinazoline derivatives and methods of use thereof
US20110053964A1 (en) *	2006-08-22	2011-03-03	Roger Tung	4-aminoquinazoline derivatives and methods of use thereof
EP2065372B1 (en)	2006-08-28	2012-11-28	Eisai R&D Management Co., Ltd.	Antitumor agent for undifferentiated gastric cancer
NZ576065A (en)	2006-09-18	2011-12-22	Boehringer Ingelheim Int	Method for treating cancer harboring egfr mutations
MX2009003673A (es) *	2006-10-04	2009-04-22	Pfizer Prod Inc	Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
EP2073803B1 (en)	2006-10-12	2018-09-19	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008044045A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008054633A1 (en) *	2006-10-31	2008-05-08	Janssen Pharmaceutica N.V.	Hydrazone derivatives as kinase inhibitors
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008076278A2 (en)	2006-12-13	2008-06-26	Schering Corporation	Methods of cancer treatment with igf1r inhibitors
EP2125781A2 (en)	2006-12-20	2009-12-02	Amgen Inc.	Substituted heterocycles and methods of use
WO2008086014A2 (en)	2007-01-09	2008-07-17	Amgen Inc.	Bis-aryl amide derivatives useful for the treatment of cancer
JP5319306B2 (ja)	2007-01-29	2013-10-16	エーザイ・アール・アンド・ディー・マネジメント株式会社	未分化型胃癌治療用組成物
CN101245050A (zh)	2007-02-14	2008-08-20	上海艾力斯医药科技有限公司	4-苯胺喹唑啉衍生物的盐
MX2009008531A (es)	2007-02-16	2009-08-26	Amgen Inc	Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EP2851091B1 (en)	2007-04-13	2017-12-27	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer resistant to ERBB therapeutics
KR20120011093A (ko) *	2007-05-09	2012-02-06	화이자 인코포레이티드	치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도
WO2008154469A1 (en) *	2007-06-11	2008-12-18	Smithkline Beecham (Cork) Limited	Quinazoline salt compounds
UY31137A1 (es) *	2007-06-14	2009-01-05	Smithkline Beecham Corp	Derivados de quinazolina como inhibidores de la pi3 quinasa
EP3330292A1 (en)	2007-08-21	2018-06-06	Amgen, Inc	Human c-fms antigen binding proteins
HRP20130649T1 (hr)	2007-09-07	2013-08-31	Agensys, Inc.	Protutijela i povezane molekule koje se vežu za 24p4c12 proteine
US20090215802A1 (en) *	2007-09-13	2009-08-27	Protia, Llc	Deuterium-enriched lapatinib
EP2207561A2 (en) *	2007-10-19	2010-07-21	Pharma Mar, S.A.	Improved antitumoral treatments
US8216571B2 (en)	2007-10-22	2012-07-10	Schering Corporation	Fully human anti-VEGF antibodies and methods of using
EP2220054A2 (en)	2007-10-29	2010-08-25	Natco Pharma Limited	Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
CN101848895B (zh)	2007-11-09	2013-10-23	卫材R&D管理有限公司	血管新生抑制物质和抗肿瘤性铂络合物的组合使用
UY31545A1 (es)	2007-12-20	2009-08-03		Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
CN101492445A (zh) *	2008-01-22	2009-07-29	孙飘扬	杂芳族化合物、其制备方法以及其用途
EP2252315A1 (en) *	2008-01-30	2010-11-24	Pharma Mar, S.A.	Improved antitumoral treatments
CN101965192A (zh) *	2008-03-07	2011-02-02	法马马有限公司	改善的抗肿瘤治疗
MY166446A (en)	2008-03-18	2018-06-27	Genentech Inc	Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents,and methods of use
WO2009137714A2 (en) *	2008-05-07	2009-11-12	Teva Pharmaceutical Industries Ltd.	Forms of lapatinib ditosylate and processes for preparation thereof
WO2009140144A1 (en) *	2008-05-15	2009-11-19	Teva Pharmaceutical Industries Ltd.	Forms of crystalline lapatinib and processes for preparation thereof
CN101584696A (zh)	2008-05-21	2009-11-25	上海艾力斯医药科技有限公司	包含喹唑啉衍生物的组合物及制备方法、用途
US20100197915A1 (en) *	2008-08-06	2010-08-05	Leonid Metsger	Lapatinib intermediates
EP2158912A1 (en)	2008-08-25	2010-03-03	Ratiopharm GmbH	Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en)	2008-08-25	2010-03-03	Ratiopharm GmbH	Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
US20100087459A1 (en) *	2008-08-26	2010-04-08	Leonid Metsger	Forms of lapatinib compounds and processes for the preparation thereof
JP5836125B2 (ja)	2008-10-16	2015-12-24	ユニバーシティオブピッツバーグ − オブザコモンウェルスシステムオブハイヤーエデュケイション	高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
WO2010061400A1 (en)	2008-11-03	2010-06-03	Natco Pharma Limited	A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts
EP2349235A1 (en)	2008-11-07	2011-08-03	Triact Therapeutics, Inc.	Use of catecholic butane derivatives in cancer therapy
KR20250123237A (ko)	2009-01-16	2025-08-14	엑셀리시스, 인코포레이티드	암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
CN101787017A (zh) *	2009-01-23	2010-07-28	岑均达	光学纯喹唑啉类化合物
WO2010090764A1 (en)	2009-02-09	2010-08-12	Supergen, Inc.	Pyrrolopyrimidinyl axl kinase inhibitors
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
JP2012519170A (ja)	2009-02-26	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100222381A1 (en)	2009-02-27	2010-09-02	Hariprasad Vankayalapati	Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2403339B1 (en)	2009-03-06	2017-01-18	Merck Sharp & Dohme Corp.	Combination cancer therapy with an akt inhibitor and other anticancer agents
JP2012520893A (ja)	2009-03-18	2012-09-10	オーエスアイ・ファーマシューティカルズ，エルエルシー	Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
ES2572728T3 (es) *	2009-03-20	2016-06-02	F. Hoffmann-La Roche Ag	Anticuerpos anti-HER biespecíficos
WO2010120386A1 (en)	2009-04-17	2010-10-21	Nektar Therapeutics	Oligomer-protein tyrosine kinase inhibitor conjugates
US8816077B2 (en)	2009-04-17	2014-08-26	Nektar Therapeutics	Oligomer-protein tyrosine kinase inhibitor conjugates
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
PT2451445T (pt)	2009-07-06	2019-07-10	Boehringer Ingelheim Int	Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010285740C1 (en)	2009-08-19	2016-03-17	Eisai R&D Management Co., Ltd.	Quinoline derivative-containing pharmaceutical composition
HUE029098T2 (en)	2009-08-21	2017-02-28	Novartis Ag	To treat lapatinib cancer
WO2011027249A2 (en)	2009-09-01	2011-03-10	Pfizer Inc.	Benzimidazole derivatives
CN102030742B (zh)	2009-09-28	2013-06-19	齐鲁制药有限公司	作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物
WO2011039759A1 (en) *	2009-09-29	2011-04-07	Natco Pharma Limited	A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
EP2510110A1 (en)	2009-11-13	2012-10-17	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
CN102079759B (zh) *	2009-12-01	2014-09-17	天津药物研究院	6位取代的喹唑啉类衍生物、其制备方法和用途
TW201129380A (en)	2009-12-04	2011-09-01	Genentech Inc	Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
PH12012501361A1 (en)	2009-12-31	2012-10-22	Centro Nac De Investigaciones Oncologicas Cnio	Tricyclic compounds for use as kinase inhibitors
ES2627703T3 (es)	2010-01-22	2017-07-31	Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii	Inhibidores de PI3·quinasa
JP5745283B2 (ja)	2010-02-12	2015-07-08	ファイザー・インク	８−フルオロ−２−｛４−［（メチルアミノ）メチル］フェニル｝−１，３，４，５−テトラヒドロ−６Ｈ−アゼピノ［５，４，３−ｃｄ］インドール−６−オンの塩および多形体
WO2011101644A1 (en)	2010-02-18	2011-08-25	Centro Nacional De Investigaciones Oncologicas (Cnio)	Triazolo [4, 5 - b] pyridin derivatives
AU2011223643A1 (en)	2010-03-03	2012-06-28	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011232219B2 (en)	2010-03-23	2016-02-04	Scinopharm Taiwan, Ltd.	Process and intermediates for preparing lapatinib
US8710221B2 (en)	2010-03-23	2014-04-29	Scinopharm Taiwan, Ltd.	Process and intermediates for preparing lapatinib
MX369728B (es)	2010-03-29	2019-11-20	Abraxis Bioscience Llc	Métodos para mejorar suministro de fármacos y efectividad de agentes terapéuticos.
MX364637B (es)	2010-03-29	2019-05-03	Abraxis Bioscience Llc Star	Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
WO2011121317A1 (en)	2010-04-01	2011-10-06	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
EP2571358B1 (en)	2010-05-21	2015-01-07	GlaxoSmithKline LLC	Combination therapy for treating cancer
US20130072507A1 (en)	2010-05-21	2013-03-21	Glaxosmithkline Llc	Combination
CA2801645A1 (en)	2010-06-04	2011-12-08	Abraxis Bioscience, Llc	Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer
CN104689314B (zh)	2010-06-16	2018-02-02	高等教育联邦系统-匹兹堡大学	内质蛋白的抗体及其用途
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
ES2573515T3 (es)	2010-06-25	2016-06-08	Eisai R&D Management Co., Ltd.	Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
JP2013539962A (ja)	2010-07-09	2013-10-31	ジェネンテック，インコーポレイテッド	抗ニューロピリン抗体及び使用方法
CN102344445B (zh) *	2010-07-23	2015-11-25	岑均达	光学纯喹唑啉类化合物
CN102344444B (zh) *	2010-07-23	2015-07-01	岑均达	光学纯喹唑啉类化合物
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
RU2013114360A (ru)	2010-08-31	2014-10-10	Дженентек, Инк.	Биомаркеры и способы лечения
ES2543151T3 (es)	2010-10-20	2015-08-17	Pfizer Inc	Derivados de 2-piridina como moduladores del receptor Smoothened
WO2012052745A1 (en)	2010-10-21	2012-04-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	Combinations of pi3k inhibitors with a second anti -tumor agent
AU2011333738A1 (en)	2010-11-24	2013-07-11	Glaxo Group Limited	Multispecific antigen binding proteins targeting HGF
CN102558159A (zh) *	2010-12-20	2012-07-11	天津药物研究院	4-取代间甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途
CN102558160B (zh) *	2010-12-20	2015-09-23	天津药物研究院	4-取代对甲磺酰胺苯胺基-喹唑啉衍生物及其制备方法和用途
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012083440A1 (en)	2010-12-23	2012-06-28	Apotex Pharmachem Inc	A process for the preparation of lapatinib and its ditosylate salt
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
WO2012098387A1 (en)	2011-01-18	2012-07-26	Centro Nacional De Investigaciones Oncológicas (Cnio)	6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
AU2012213080B2 (en)	2011-01-31	2014-03-27	Novartis Ag	Novel heterocyclic derivatives
WO2012116040A1 (en)	2011-02-22	2012-08-30	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
BR112013022307A2 (pt)	2011-03-04	2020-09-24	Glaxosmithkline Intellectual Property (No. 2) Limited	aminoquinolinas como inibidores de quinase
SG10201913982WA (en)	2011-03-04	2020-03-30	Newgen Therapeutics Inc	Alkyne Substituted Quinazoline Compound And Methods Of Use
US10952415B2 (en)	2011-03-09	2021-03-23	Richard G. Pestell	Prostate cancer cell lines, gene signatures and uses thereof
CN103648500B (zh)	2011-03-17	2016-05-04	宾夕法尼亚大学理事会	双功能酶制钳型分子的方法和用途
US9295676B2 (en)	2011-03-17	2016-03-29	The Trustees Of The University Of Pennsylvania	Mutation mimicking compounds that bind to the kinase domain of EGFR
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
MX2013010871A (es)	2011-03-23	2014-01-31	Amgen Inc	Inhibidores dobles triciclicos fusionados de cdk 4/6 y flt3.
WO2012135753A1 (en)	2011-04-01	2012-10-04	Genentech, Inc.	Combinations of akt inhibitor compounds and erlotinib, and methods of use
US9150644B2 (en)	2011-04-12	2015-10-06	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
JP6021805B2 (ja)	2011-04-18	2016-11-09	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
ES2724801T3 (es)	2011-04-19	2019-09-16	Pfizer	Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN102918029B (zh) *	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2012257513B2 (en)	2011-05-19	2017-05-11	Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Macrocyclic compounds as protein kinase inhibitors
EP2524918A1 (en)	2011-05-19	2012-11-21	Centro Nacional de Investigaciones Oncológicas (CNIO)	Imidazopyrazines derivates as kinase inhibitors
ITMI20110894A1 (it) *	2011-05-20	2012-11-21	Italiana Sint Spa	Impurezza del lapatinib e suoi sali
JP5414739B2 (ja)	2011-05-25	2014-02-12	三菱電機株式会社	半導体テスト治具
EP3444363B1 (en)	2011-06-03	2020-11-25	Eisai R&D Management Co., Ltd.	Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
WO2013005057A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	New compounds
WO2013004984A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncologicas (Cnio)	Tricyclic compounds for use as kinase inhibitors
WO2013005041A1 (en)	2011-07-07	2013-01-10	Centro Nacional De Investigaciones Oncológicas (Cnio)	Tricyclic heterocyclic compounds as kinase inhibitors
PT3409278T (pt)	2011-07-21	2020-12-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de proteína cinase heterocíclicos
US9499530B2 (en) *	2011-08-01	2016-11-22	Hangzhou Minsheng Institutes For Pharma Research	Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament
WO2013025939A2 (en)	2011-08-16	2013-02-21	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
TWI547494B (zh)	2011-08-18	2016-09-01	葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之胺基喹唑啉類
BR112014004762A2 (pt)	2011-08-31	2018-06-19	Genentech Inc	métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula
CA2847540C (en)	2011-09-22	2016-05-17	Pfizer Inc.	Pyrrolopyrimidine and purine derivatives
SG11201400996SA (en)	2011-09-30	2014-04-28	Genentech Inc	Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013050725A1 (en)	2011-10-04	2013-04-11	King's College London	Ige anti -hmw-maa antibody
PH12014500912A1 (en)	2011-10-28	2014-06-09	Novartis Ag	Novel purine derivatives and their use in the treatment of disease
BR112014011115A2 (pt)	2011-11-08	2017-06-13	Pfizer	métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf
WO2013080218A1 (en)	2011-11-28	2013-06-06	Fresenius Kabi Oncology Ltd.	Novel intermediates and process for the preparation of lapatinib and its pharmaceutically acceptable salts
RU2014135224A (ru)	2012-01-31	2016-03-27	Смитклайн Бичем (Корк) Лимитед	Способ лечения злокачественных опухолей
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
JP2015512425A (ja)	2012-04-03	2015-04-27	ノバルティスアーゲー	チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2013173312A1 (en)	2012-05-14	2013-11-21	Pestell Richard G	Using modulators of ccr5 for treating cancer
US10213432B2 (en)	2012-05-16	2019-02-26	Novartis Ag	Dosage regimen for a PI-3 kinase inhibitor
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
US9505749B2 (en)	2012-08-29	2016-11-29	Amgen Inc.	Quinazolinone compounds and derivatives thereof
AR092529A1 (es)	2012-09-13	2015-04-22	Glaxosmithkline Llc	Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
US9394257B2 (en)	2012-10-16	2016-07-19	Tolero Pharmaceuticals, Inc.	PKM2 modulators and methods for their use
CZ2012712A3 (cs)	2012-10-17	2014-04-30	Zentiva, K.S.	Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN102942561A (zh) *	2012-11-06	2013-02-27	深圳海王药业有限公司	4-氨基喹唑啉杂环化合物及其用途
US9260426B2 (en)	2012-12-14	2016-02-16	Arrien Pharmaceuticals Llc	Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
BR112015009004A8 (pt)	2012-12-21	2021-07-20	Eisai R&D Man Co Ltd	forma amorfa de derivado de quinolina e método de produção da mesma
CN103896889B (zh) *	2012-12-27	2016-05-25	上海创诺制药有限公司	拉帕替尼中间体及其制备方法和应用
JP6669499B2 (ja)	2013-02-15	2020-03-18	カラファーマシューティカルズインコーポレイテッド	治療用化合物
SI2958552T1 (sl)	2013-02-19	2017-08-31	Hexal Ag	Farmacevtski sestavek, ki sestoji iz n-(3-kloro-4-(3-fluorobenziloksi) fenil)-6-(5(((2-(metilsulfonil)etil)amino)metil)-2-furil)kinazolin-4- amina ali farmacevtsko sprejemljive soli, solvata ali njegove solvirane soli
US9688688B2 (en)	2013-02-20	2017-06-27	Kala Pharmaceuticals, Inc.	Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CA2900680C (en)	2013-02-20	2021-08-10	Kala Pharmaceuticals, Inc.	Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases
TWI630203B (zh)	2013-02-21	2018-07-21	葛蘭素史克智慧財產發展有限公司	做為激酶抑制劑的喹唑啉類
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
CN103159747A (zh) *	2013-02-26	2013-06-19	常州鸿创高分子科技有限公司	一种二对甲苯磺酸拉帕替尼的合成方法
EP2961412A4 (en)	2013-02-26	2016-11-09	Triact Therapeutics Inc	CANCER THERAPY
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
WO2014138364A2 (en)	2013-03-06	2014-09-12	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
WO2014153030A2 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
ES2738493T3 (es)	2013-03-14	2020-01-23	Tolero Pharmaceuticals Inc	Inhibidores de JAK2 y ALK2 y métodos para su uso
MX2015011899A (es)	2013-03-15	2016-05-05	Genentech Inc	Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
WO2014147246A1 (en)	2013-03-21	2014-09-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014170910A1 (en)	2013-04-04	2014-10-23	Natco Pharma Limited	Process for the preparation of lapatinib
US9206188B2 (en)	2013-04-18	2015-12-08	Arrien Pharmaceuticals Llc	Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
US10517861B2 (en)	2013-05-14	2019-12-31	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
HU231012B1 (hu)	2013-05-24	2019-11-28	Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság	Lapatinib sók
EP3022186B1 (en) *	2013-07-18	2020-02-26	Shanghai Fochon Pharmaceutical Co. Ltd	Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
US9381246B2 (en)	2013-09-09	2016-07-05	Triact Therapeutics, Inc.	Cancer therapy
WO2015051304A1 (en)	2013-10-04	2015-04-09	Aptose Biosciences Inc.	Compositions, biomarkers and their use in treatment of cancer
US9890173B2 (en)	2013-11-01	2018-02-13	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
AU2014342042B2 (en)	2013-11-01	2017-08-17	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
CN103554091B (zh) *	2013-11-05	2016-05-18	沈阳工业大学	喹唑啉衍生物及其制备方法和用途
UA115388C2 (uk)	2013-11-21	2017-10-25	Пфайзер Інк.	2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CA2930359C (en)	2013-12-06	2022-03-01	Novartis Ag	Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
PL3097107T3 (pl)	2014-01-24	2020-01-31	Turning Point Therapeutics, Inc.	Diarylowe związki makrocykliczne jako modulatory kinaz białkowych
US20160361309A1 (en)	2014-02-26	2016-12-15	Glaxosmithkline Intellectual Property (No.2) Limited	Methods of treating cancer patients responding to ezh2 inhibitor gsk126
WO2015148531A1 (en)	2014-03-24	2015-10-01	Genentech, Inc.	Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
WO2015155624A1 (en)	2014-04-10	2015-10-15	Pfizer Inc.	Dihydropyrrolopyrimidine derivatives
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
EP2937346A1 (en)	2014-04-24	2015-10-28	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Co-crystals of lapatinib
KR20160149256A (ko)	2014-04-30	2016-12-27	화이자 인코포레이티드	시클로알킬-결합된 디헤테로사이클 유도체
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
WO2016001789A1 (en)	2014-06-30	2016-01-07	Pfizer Inc.	Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
EP3473271B1 (en)	2014-07-31	2022-07-20	The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services	Human monoclonal antibodies against epha4 and their use
JP6659554B2 (ja)	2014-08-28	2020-03-04	エーザイ・アール・アンド・ディー・マネジメント株式会社	高純度キノリン誘導体およびその製造方法
JP2017536347A (ja)	2014-10-17	2017-12-07	ノバルティスアーゲー	セリチニブとｅｇｆｒ阻害剤の組合せ
CA3081443A1 (en)	2014-12-15	2016-06-23	The Regents Of The University Of Michigan	Small molecule inhibitors of egfr and pi3k
EP3233829B1 (en)	2014-12-18	2019-08-14	Pfizer Inc	Pyrimidine and triazine derivatives and their use as axl inhibitors
EP3699290A1 (en)	2014-12-24	2020-08-26	F. Hoffmann-La Roche AG	Therapeutic, diagnostic, and prognostic methods for cancer
CN105801565B (zh) *	2014-12-30	2020-04-03	天津法莫西医药科技有限公司	N-[3-氯-4-[(3-氟苯基)甲氧基]苯基]-6-[(5-甲酰基)呋喃-2-基]-4-喹唑啉胺制备方法
ES2887474T3 (es)	2015-01-08	2021-12-22	Univ Leland Stanford Junior	Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
JP2018504441A (ja) *	2015-02-03	2018-02-15	トリリウムセラピューティクスインコーポレイテッド	癌の治療に有用なｅｇｆｒ阻害剤としての新規フッ素化誘導体
LT3263106T (lt)	2015-02-25	2024-01-10	Eisai R&D Management Co., Ltd.	Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
HK1251655A1 (zh)	2015-04-20	2019-02-01	Tolero Pharmaceuticals, Inc.	通过线粒体分析预测对阿伏西地的应答
CN107709344B (zh)	2015-05-01	2022-07-15	共晶制药股份有限公司	用于治疗黄病毒科病毒和癌症的核苷类似物
EP4086264B1 (en)	2015-05-18	2023-10-25	Sumitomo Pharma Oncology, Inc.	Alvocidib prodrugs having increased bioavailability
CN106279307B (zh) *	2015-05-19	2019-07-26	正大天晴药业集团股份有限公司	芳氨代葡萄糖衍生物、其制备方法及抗肿瘤用途
AU2016279474B2 (en)	2015-06-16	2021-09-09	Eisai R&D Management Co., Ltd.	Anticancer agent
CN111643479B (zh)	2015-07-01	2023-10-27	加州理工学院	基于阳离子粘酸聚合物的递送系统
EP3317285B1 (en)	2015-07-02	2021-01-27	Turning Point Therapeutics, Inc.	Chiral diaryl macrocycles as modulators of protein kinases
RS65593B1 (sr)	2015-07-06	2024-06-28	Turning Point Therapeutics Inc	Polimorf diaril makrocikla
WO2017009751A1 (en)	2015-07-15	2017-01-19	Pfizer Inc.	Pyrimidine derivatives
PL3733187T3 (pl)	2015-07-21	2025-01-07	Turning Point Therapeutics, Inc.	Chiralny makrocykl diarylowy i jego zastosowanie w leczeniu raka
US10568887B2 (en)	2015-08-03	2020-02-25	Tolero Pharmaceuticals, Inc.	Combination therapies for treatment of cancer
WO2017025871A1 (en)	2015-08-07	2017-02-16	Glaxosmithkline Intellectual Property Development Limited	Combination therapy comprising anti ctla-4 antibodies
SG11201801083UA (en)	2015-08-20	2018-03-28	Eisai R&D Man Co Ltd	Tumor therapeutic agent
EP3350181B1 (en) *	2015-09-02	2023-11-01	The Regents of The University of California	Her3 ligands and uses thereof
CN106632276B (zh) *	2015-10-28	2021-06-15	上海天慈生物谷生物工程有限公司	一种治疗乳腺癌药物的制备方法
CN108472289A (zh)	2015-11-02	2018-08-31	诺华股份有限公司	磷脂酰肌醇3-激酶抑制剂的给药方案
EP3383907B1 (en)	2015-12-01	2022-02-23	GlaxoSmithKline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
WO2017096165A1 (en)	2015-12-03	2017-06-08	Agios Pharmaceuticals, Inc.	Mat2a inhibitors for treating mtap null cancer
CN109195593A (zh)	2016-03-15	2019-01-11	奥莱松基因组股份有限公司	用于治疗实体瘤的lsd1抑制剂的组合
CA3031100A1 (en)	2016-07-28	2018-02-01	Tp Therapeutics, Inc.	Macrocycle kinase inhibitors
WO2018025221A1 (en)	2016-08-04	2018-02-08	Glaxosmithkline Intellectual Property Development Limited	Anti-icos and anti-pd-1 antibody combination therapy
CA3036340A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en)	2016-09-08	2020-08-13	KALA BIO, Inc.	Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en)	2016-09-08	2018-03-15	Kala Pharmaceuticals, Inc.	Crystalline forms of therapeutic compounds and uses thereof
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US11279694B2 (en)	2016-11-18	2022-03-22	Sumitomo Dainippon Pharma Oncology, Inc.	Alvocidib prodrugs and their use as protein kinase inhibitors
MX2019007332A (es)	2016-12-19	2019-11-18	Tolero Pharmaceuticals Inc	Péptidos indicadores y métodos para caracterizar sensibilidad.
EA201991528A1 (ru)	2016-12-22	2020-01-16	Эмджен Инк.	БЕНЗИЗОТИАЗОЛЬНЫЕ, ИЗОТИАЗОЛО[3,4-b]ПИРИДИНОВЫЕ, ХИНАЗОЛИНОВЫЕ, ФТАЛАЗИНОВЫЕ, ПИРИДО[2,3-d]ПИРИДАЗИНОВЫЕ И ПИРИДО[2,3-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ G12C KRAS ДЛЯ ЛЕЧЕНИЯ РАКА ЛЕГКОГО, РАКА ПОДЖЕЛУДОЧНОЙ ЖЕЛЕЗЫ ИЛИ КОЛОРЕКТАЛЬНОГО РАКА
TWI808958B (zh)	2017-01-25	2023-07-21	美商特普醫葯公司	涉及二芳基巨環化合物之組合療法
CN110072528B (zh)	2017-02-08	2022-04-26	卫材R&D管理有限公司	治疗肿瘤的药物组合物
KR20200013644A (ko)	2017-05-16	2020-02-07	에자이 알앤드디 매니지먼트 가부시키가이샤	간세포 암종의 치료
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
PL3658148T3 (pl)	2017-07-28	2024-10-07	Turning Point Therapeutics, Inc.	Związki makrocykliczne i ich zastosowania
ES2985118T3 (es)	2017-09-08	2024-11-04	Amgen Inc	Inhibidores de KRAS G12C y métodos de uso de los mismos
JP7196160B2 (ja)	2017-09-12	2022-12-26	スミトモファーマオンコロジー，インコーポレイテッド	Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019075367A1 (en)	2017-10-13	2019-04-18	Tolero Pharmaceuticals, Inc.	PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
JP2021506974A (ja)	2017-12-18	2021-02-22	スターングリーン、インク．	チロシンキナーゼ阻害剤として有用なピリミジン化合物
AU2018392332B2 (en)	2017-12-19	2023-08-03	Turning Point Therapeutics, Inc.	Macrocyclic compounds for treating disease
EP3788038B1 (en)	2018-05-04	2023-10-11	Amgen Inc.	Kras g12c inhibitors and methods of using the same
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
MA52564A (fr)	2018-05-10	2021-03-17	Amgen Inc	Inhibiteurs de kras g12c pour le traitement du cancer
MX2020012731A (es)	2018-06-01	2021-02-22	Amgen Inc	Inhibidores de kras g12c y metodos para su uso.
EP4268898A3 (en)	2018-06-11	2024-01-17	Amgen Inc.	Kras g12c inhibitors for treating cancer
EP3807276B1 (en)	2018-06-12	2025-12-10	Amgen Inc.	Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
WO2019241327A1 (en)	2018-06-13	2019-12-19	California Institute Of Technology	Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
US12350272B2 (en) *	2018-06-27	2025-07-08	Oscotec Inc.	Pyridopyrimidinone derivatives for use as AXL inhibitors
US11040038B2 (en)	2018-07-26	2021-06-22	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
EP3860608A1 (en)	2018-10-04	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Egfr inhibitors for treating keratodermas
JP7516029B2 (ja)	2018-11-16	2024-07-16	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7454572B2 (ja)	2018-11-19	2024-03-22	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤及びその使用方法
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
AU2019391097B2 (en)	2018-12-04	2025-07-03	Sumitomo Pharma America, Inc.	CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US12351571B2 (en)	2018-12-19	2025-07-08	Array Biopharma Inc.	Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
JP2022515198A (ja)	2018-12-19	2022-02-17	アレイバイオファーマインコーポレイテッド	ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
KR102875569B1 (ko)	2018-12-20	2025-10-23	암젠 인크	Kif18a 억제제
US12459932B2 (en)	2018-12-20	2025-11-04	Amgen Inc.	KIF18A inhibitors
US12441736B2 (en)	2018-12-20	2025-10-14	Amgen Inc.	KIF18A inhibitors
MX419368B (es)	2018-12-20	2025-01-14	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a
US20220071999A1 (en) *	2018-12-21	2022-03-10	University Of Notre Dame Du Lac	Design and discovery of bd oxidase inhibitors for the treatment of mycobacterial diseases
CN113795512A (zh)	2019-02-01	2021-12-14	葛兰素史克知识产权开发有限公司	包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
NZ778055A (en)	2019-02-12	2025-11-28	Sumitomo Pharma America Inc	Formulations comprising heterocyclic protein kinase inhibitors
EP3930845A1 (en)	2019-03-01	2022-01-05	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
WO2020180768A1 (en)	2019-03-01	2020-09-10	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
JP2022525149A (ja)	2019-03-20	2022-05-11	スミトモダイニッポンファーマオンコロジー，インコーポレイテッド	ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (en)	2019-03-22	2022-01-26	Sumitomo Dainippon Pharma Oncology, Inc.	Compositions comprising pkm2 modulators and methods of treatment using the same
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
KR20250159270A (ko)	2019-05-21	2025-11-10	암젠 인크	고체 상태 형태
KR20220026585A (ko)	2019-06-26	2022-03-04	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	Il1rap 결합 단백질
WO2021026100A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Pyridine derivatives as kif18a inhibitors
WO2021026099A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
WO2021026101A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
EP4007752B1 (en)	2019-08-02	2025-09-24	Amgen Inc.	Kif18a inhibitors
WO2021046289A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
MX2022004656A (es)	2019-10-24	2022-05-25	Amgen Inc	Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
KR20220109408A (ko)	2019-11-04	2022-08-04	레볼루션 메디슨즈, 인크.	Ras 억제제
CN114901366A (zh)	2019-11-04	2022-08-12	锐新医药公司	Ras抑制剂
PH12022550988A1 (en)	2019-11-04	2023-10-09	Revolution Medicines Inc	Ras inhibitors
WO2021092115A1 (en)	2019-11-08	2021-05-14	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
CA3161156A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
AR120457A1 (es)	2019-11-14	2022-02-16	Amgen Inc	Síntesis mejorada del compuesto inhibidor de g12c de kras
WO2021108683A1 (en)	2019-11-27	2021-06-03	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
WO2021142026A1 (en)	2020-01-07	2021-07-15	Revolution Medicines, Inc.	Shp2 inhibitor dosing and methods of treating cancer
CN115038466A (zh)	2020-01-28	2022-09-09	葛兰素史密斯克莱知识产权发展有限公司	联合治疗及其用途和方法
WO2021155006A1 (en)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibitors of cyclin-dependent kinases and uses thereof
BR112022017425A2 (pt) *	2020-03-02	2022-11-29	Turning Point Therapeutics Inc	Usos terapêuticos de compostos macrocíclicos
MX2022016355A (es)	2020-06-18	2023-04-03	Revolution Medicines Inc	Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
CA3187757A1 (en)	2020-09-03	2022-03-24	Ethan AHLER	Use of sos1 inhibitors to treat malignancies with shp2 mutations
IL301298A (en)	2020-09-15	2023-05-01	Revolution Medicines Inc	Indole derivatives as RAS inhibitors in cancer therapy
AU2021409816A1 (en)	2020-12-22	2023-07-06	Qilu Regor Therapeutics Inc.	Sos1 inhibitors and uses thereof
JP2024501995A (ja)	2020-12-22	2024-01-17	メカニスティク・セラピューティクス・エルエルシー	Ｅｇｆｒ及び／又はｐｉ３ｋ阻害剤としての置換アミノベンジルヘテロアリール化合物
WO2022221227A1 (en)	2021-04-13	2022-10-20	Nuvalent, Inc.	Amino-substituted heterocycles for treating cancers with egfr mutations
WO2022235866A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
AR125787A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
AR125782A1 (es)	2021-05-05	2023-08-16	Revolution Medicines Inc	Inhibidores de ras
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
CN119212994A (zh)	2021-12-17	2024-12-27	建新公司	作为shp2抑制剂的吡唑并吡嗪化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
JP2025509217A (ja)	2022-03-07	2025-04-11	アムジエン・インコーポレーテツド	４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
CN120504682A (zh)	2022-06-10	2025-08-19	锐新医药公司	大环ras抑制剂
JP2025536257A (ja)	2022-10-14	2025-11-05	ブラックダイアモンドセラピューティクス，インコーポレイティド	イソキノリンまたは６－ａｚａ－キノリン誘導体を使用してがんを治療する方法
KR20250164828A (ko)	2023-03-30	2025-11-25	레볼루션 메디슨즈, 인크.	Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
CN121263418A (zh)	2023-04-07	2026-01-02	锐新医药公司	大环ras抑制剂
KR20260005904A (ko)	2023-04-07	2026-01-12	레볼루션 메디슨즈, 인크.	매크로사이클릭 ras 억제제
TW202448897A (zh)	2023-04-14	2024-12-16	美商銳新醫藥公司	Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
CN121100123A (zh)	2023-04-14	2025-12-09	锐新医药公司	Ras抑制剂的结晶形式
TW202508595A (zh)	2023-05-04	2025-03-01	美商銳新醫藥公司	用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en)	2023-08-07	2025-02-13	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025080946A2 (en)	2023-10-12	2025-04-17	Revolution Medicines, Inc.	Ras inhibitors
TW202542151A (zh)	2023-12-22	2025-11-01	美商銳格醫藥有限公司	Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (en)	2024-02-09	2025-08-14	Revolution Medicines, Inc.	Ras inhibitors
WO2025240847A1 (en)	2024-05-17	2025-11-20	Revolution Medicines, Inc.	Ras inhibitors
WO2025255438A1 (en)	2024-06-07	2025-12-11	Revolution Medicines, Inc.	Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en)	2024-06-21	2025-12-26	Revolution Medicines, Inc.	Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en)	2024-06-28	2026-01-02	Revolution Medicines, Inc.	Ras inhibitors
WO2026015801A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015825A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder
WO2026015790A1 (en)	2024-07-12	2026-01-15	Revolution Medicines, Inc.	Methods of treating a ras related disease or disorder

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4074057A (en)	1973-12-12	1978-02-14	Takeda Chemical Co., Ltd.	2-Halopropionic acid and its derivatives
US4166735A (en)	1977-01-21	1979-09-04	Shell Oil Company	Cycloalkanecarboxanilide derivative herbicides
WO1986006718A1 (en)	1985-05-17	1986-11-20	The Australian National University	Antimalarial compounds
US5141941A (en)	1988-11-21	1992-08-25	Ube Industries, Ltd.	Aralkylamine derivatives, and fungicides containing the same
US5034393A (en)	1989-07-27	1991-07-23	Dowelanco	Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
EP0452002A3 (en)	1990-03-30	1992-02-26	Dowelanco	Thienopyrimidine derivatives
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE4131924A1 (de)	1991-09-25	1993-07-08	Hoechst Ag	Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
GB9127252D0 (en)	1991-12-23	1992-02-19	Boots Co Plc	Therapeutic agents
AU661533B2 (en)	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
WO1993017682A1 (en)	1992-03-04	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
WO1993018035A1 (en)	1992-03-04	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
US5326766A (en)	1992-08-19	1994-07-05	Dreikorn Barry A	4-(2-(4-(2-pyridinyloxy)phenyl)ethoxy)quinazoline and analogues thereof
DE4308014A1 (de)	1993-03-13	1994-09-15	Hoechst Schering Agrevo Gmbh	Kondensierte Stickstoffheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9312891D0 (en)	1993-06-22	1993-08-04	Boots Co Plc	Therapeutic agents
US5654307A (en)	1994-01-25	1997-08-05	Warner-Lambert Company	Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1995024190A2 (en)	1994-03-07	1995-09-14	Sugen, Inc.	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (is) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en)	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
DK0831829T3 (da)	1995-06-07	2003-12-15	Pfizer	Heterocykliske, ringkondenserede pyrimidinderivater
GB9514265D0 (en)	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
PL321296A1 (en)	1995-11-14	1997-12-08	Pharmacia & Upjohn Spa	Derivatives of aryl and heteroaryl purine
GB9603095D0 (en)	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
ES2191187T3 (es)	1996-07-13	2003-09-01	Glaxo Group Ltd	Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en) *	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
EP0912559B1 (en)	1996-07-13	2002-11-06	Glaxo Group Limited	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
RS49779B (sr)	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
JP4044839B2 (ja) *	2000-06-22	2008-02-06	ファイザー・プロダクツ・インク	異常細胞増殖を治療するための置換２環式誘導体
MXPA02012681A (es) *	2000-06-30	2003-04-25	Glaxo Group Ltd	Compuestos de sales de ditosilato de quinazolina.
JP4458746B2 (ja) *	2001-01-16	2010-04-28	グラクソグループリミテッド	癌の治療方法
US7268230B2 (en) *	2002-02-01	2007-09-11	Astrazeneca Ab	Quinazoline compounds
US7488823B2 (en) *	2003-11-10	2009-02-10	Array Biopharma, Inc.	Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors

1998
- 1998-01-12 RS YUP-448/00A patent/RS49779B/sr unknown
- 1998-01-12 GB GBGB9800569.7A patent/GB9800569D0/en not_active Ceased
1999
- 1999-01-08 AT AT99902522T patent/ATE270670T1/de active
- 1999-01-08 MA MA25422A patent/MA26596A1/fr unknown
- 1999-01-08 PT PT04076762T patent/PT1454907E/pt unknown
- 1999-01-08 TR TR2000/02015T patent/TR200002015T2/xx unknown
- 1999-01-08 SI SI9930902T patent/SI1460072T1/sl unknown
- 1999-01-08 AP APAP/P/2000/001861A patent/AP1446A/en active
- 1999-01-08 SK SK1050-2000A patent/SK285405B6/sk not_active IP Right Cessation
- 1999-01-08 US US09/582,746 patent/US6727256B1/en not_active Expired - Lifetime
- 1999-01-08 IL IL13704199A patent/IL137041A0/xx not_active IP Right Cessation
- 1999-01-08 PT PT99902522T patent/PT1047694E/pt unknown
- 1999-01-08 ES ES04076761T patent/ES2262087T3/es not_active Expired - Lifetime
- 1999-01-08 CA CA002317589A patent/CA2317589C/en not_active Expired - Lifetime
- 1999-01-08 CN CNB998038873A patent/CN1134438C/zh not_active Expired - Lifetime
- 1999-01-08 DE DE122008000048C patent/DE122008000048I1/de active Pending
- 1999-01-08 EE EEP200000411A patent/EE04616B1/xx active Protection Beyond IP Right Term
- 1999-01-08 SI SI9931027T patent/SI1454907T1/sl unknown
- 1999-01-08 AT AT04076761T patent/ATE322491T1/de active
- 1999-01-08 CZ CZ20002587A patent/CZ298047B6/cs not_active IP Right Cessation
- 1999-01-08 HU HU0100941A patent/HU227593B1/hu active Protection Beyond IP Right Term
- 1999-01-08 SI SI9930663T patent/SI1047694T1/xx unknown
- 1999-01-08 WO PCT/EP1999/000048 patent/WO1999035146A1/en not_active Ceased
- 1999-01-08 EP EP99902522A patent/EP1047694B1/en not_active Expired - Lifetime
- 1999-01-08 UA UA2000074012A patent/UA66827C2/uk unknown
- 1999-01-08 DE DE69930773T patent/DE69930773T2/de not_active Expired - Lifetime
- 1999-01-08 PL PL341595A patent/PL192746B1/pl unknown
- 1999-01-08 EA EA200000637A patent/EA002455B1/ru not_active IP Right Cessation
- 1999-01-08 HR HR20000469A patent/HRP20000469B1/xx not_active IP Right Cessation
- 1999-01-08 GE GEAP19995454A patent/GEP20022678B/en unknown
- 1999-01-08 AT AT04076762T patent/ATE417847T1/de active
- 1999-01-08 NZ NZ505456A patent/NZ505456A/xx not_active IP Right Cessation
- 1999-01-08 EP EP04076762A patent/EP1454907B1/en not_active Expired - Lifetime
- 1999-01-08 ES ES04076762T patent/ES2319119T3/es not_active Expired - Lifetime
- 1999-01-08 AU AU22783/99A patent/AU749549C/en not_active Revoked
- 1999-01-08 CO CO99001037A patent/CO4820390A1/es unknown
- 1999-01-08 KR KR1020007007635A patent/KR100569776B1/ko not_active Expired - Lifetime
- 1999-01-08 ES ES99902522T patent/ES2221354T3/es not_active Expired - Lifetime
- 1999-01-08 ME MEP-2000-448A patent/ME00757B/me unknown
- 1999-01-08 JP JP2000527545A patent/JP3390741B2/ja not_active Expired - Lifetime
- 1999-01-08 PT PT04076761T patent/PT1460072E/pt unknown
- 1999-01-08 DK DK99902522T patent/DK1047694T3/da active
- 1999-01-08 EP EP04076761A patent/EP1460072B1/en not_active Expired - Lifetime
- 1999-01-08 DK DK04076762T patent/DK1454907T3/da active
- 1999-01-08 BR BRPI9906904-0A patent/BR9906904B1/pt not_active IP Right Cessation
- 1999-01-08 DK DK04076761T patent/DK1460072T3/da active
- 1999-01-08 DE DE69918528T patent/DE69918528T2/de not_active Expired - Lifetime
- 1999-01-08 DE DE69940128T patent/DE69940128D1/de not_active Expired - Lifetime
- 1999-01-11 MY MYPI99000090A patent/MY124055A/en unknown
- 1999-01-11 AR ARP990100083A patent/AR015507A1/es active IP Right Grant
- 1999-01-11 ZA ZA9900172A patent/ZA99172B/xx unknown
- 1999-01-11 EG EG2699A patent/EG24743A/xx active
- 1999-01-11 PE PE1999000020A patent/PE20000230A1/es not_active IP Right Cessation
- 1999-01-12 TW TW088100388A patent/TW477788B/zh active
2000
- 2000-06-27 IS IS5549A patent/IS2276B/is unknown
- 2000-06-27 IL IL137041A patent/IL137041A/en active Protection Beyond IP Right Term
- 2000-07-07 OA OA1200000202A patent/OA11444A/en unknown
- 2000-07-11 NO NO20003561A patent/NO316176B1/no not_active IP Right Cessation
- 2000-08-07 BG BG104668A patent/BG64825B1/bg unknown
2002
- 2002-02-08 US US10/071,358 patent/US6713485B2/en not_active Expired - Lifetime
- 2002-03-28 JP JP2002092102A patent/JP2002326990A/ja active Pending
2003
- 2003-01-15 US US10/342,810 patent/US20030176451A1/en not_active Abandoned
2005
- 2005-02-03 US US11/050,033 patent/US7109333B2/en not_active Expired - Lifetime
2006
- 2006-06-19 CY CY20061100812T patent/CY1105618T1/el unknown
- 2006-09-19 US US11/532,926 patent/US20070015775A1/en not_active Abandoned
- 2006-11-10 HR HR20060387A patent/HRP20060387A2/xx not_active Application Discontinuation
2007
- 2007-05-23 US US11/752,582 patent/US20070238875A1/en not_active Abandoned
2008
- 2008-06-12 AR ARP080102516A patent/AR066982A2/es unknown
- 2008-09-10 LU LU91475C patent/LU91475I2/fr unknown
- 2008-09-12 NL NL300360C patent/NL300360I2/nl unknown
- 2008-09-18 CY CY200800015C patent/CY2008015I1/el unknown
- 2008-10-01 FR FR08C0038C patent/FR08C0038I2/fr active Active
- 2008-11-13 NO NO2008017C patent/NO2008017I1/no not_active IP Right Cessation
2009
- 2009-03-06 CY CY20091100253T patent/CY1108859T1/el unknown
2010
- 2010-01-22 US US12/691,784 patent/US8513262B2/en not_active Expired - Fee Related
- 2010-12-17 AU AU2010276460A patent/AU2010276460A1/en active Pending
2013
- 2013-07-16 US US13/943,049 patent/US8912205B2/en not_active Expired - Fee Related
2014
- 2014-11-10 US US14/536,896 patent/US9199973B2/en not_active Expired - Fee Related
2015
- 2015-10-20 US US14/887,434 patent/US20160051551A1/en not_active Abandoned
2016
- 2016-08-03 US US15/226,949 patent/US20160339027A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69930773T2 (de)	2006-09-28
EE200000411A (et)	2001-12-17
DK1460072T3 (da)	2006-07-31
CN1134438C (zh)	2004-01-14
NL300360I2 (nl)	2009-02-02
LU91475I9 (is)	2019-01-02
IS5549A (is)	2000-06-27
SI1047694T1 (en)	2005-02-28
AU2010276460A1 (en)	2011-02-17
US9199973B2 (en)	2015-12-01
EP1454907B1 (en)	2008-12-17
CY2008015I2 (el)	2009-11-04
AP1446A (en)	2005-07-19
WO1999035146A1 (en)	1999-07-15
HUP0100941A2 (hu)	2001-09-28
ATE322491T1 (de)	2006-04-15
ME00757B (me)	2008-06-05
EA200000637A1 (ru)	2001-02-26
LU91475I2 (fr)	2008-11-10
MY124055A (en)	2006-06-30
KR20010015902A (ko)	2001-02-26
EP1047694A1 (en)	2000-11-02
US7109333B2 (en)	2006-09-19
HRP20000469A2 (en)	2001-06-30
DK1454907T3 (da)	2009-03-09
SI1454907T1 (sl)	2009-04-30
DE69918528T2 (de)	2005-07-28
HU227593B1 (en)	2011-09-28
US20070238875A1 (en)	2007-10-11
US20160051551A1 (en)	2016-02-25
US20130310562A1 (en)	2013-11-21
NL300360I1 (nl)	2008-11-03
SK10502000A3 (sk)	2001-08-06
CY1108859T1 (el)	2014-07-02
US20050130996A1 (en)	2005-06-16
IL137041A (en)	2006-10-05
EA002455B1 (ru)	2002-04-25
EP1454907A1 (en)	2004-09-08
UA66827C2 (uk)	2004-06-15
US20100120804A1 (en)	2010-05-13
EE04616B1 (et)	2006-04-17
HRP20000469B1 (hr)	2007-05-31
CZ298047B6 (cs)	2007-06-06
US6727256B1 (en)	2004-04-27
DK1047694T3 (da)	2004-11-08
US8912205B2 (en)	2014-12-16
SI1460072T1 (sl)	2006-08-31
PT1454907E (pt)	2009-02-18
CO4820390A1 (es)	1999-07-28
NO20003561D0 (no)	2000-07-11
CN1292788A (zh)	2001-04-25
ES2319119T3 (es)	2009-05-04
DE69930773D1 (de)	2006-05-18
BR9906904B1 (pt)	2011-05-03
US6713485B2 (en)	2004-03-30
ZA99172B (en)	2000-07-11
KR100569776B1 (ko)	2006-04-11
YU44800A (sh)	2002-11-15
PL192746B1 (pl)	2006-12-29
OA11444A (en)	2004-04-29
ES2262087T3 (es)	2006-11-16
AU2278399A (en)	1999-07-26
TR200002015T2 (tr)	2001-01-22
BG104668A (en)	2001-04-30
US20160339027A1 (en)	2016-11-24
CY1105618T1 (el)	2010-12-22
ATE417847T1 (de)	2009-01-15
BR9906904A (pt)	2000-10-17
US20070015775A1 (en)	2007-01-18
FR08C0038I1 (is)	2008-11-14
GB9800569D0 (en)	1998-03-11
EP1460072B1 (en)	2006-04-05
JP2002500225A (ja)	2002-01-08
AU749549C (en)	2003-03-20
US20020147205A1 (en)	2002-10-10
EG24743A (en)	2010-07-14
DE69918528D1 (de)	2004-08-12
US20150065527A1 (en)	2015-03-05
MA26596A1 (fr)	2004-12-20
PE20000230A1 (es)	2000-04-03
CA2317589A1 (en)	1999-07-15
PL341595A1 (en)	2001-04-23
US8513262B2 (en)	2013-08-20
AR066982A2 (es)	2009-09-23
CY2008015I1 (el)	2009-11-04
FR08C0038I2 (fr)	2012-02-22
RS49779B (sr)	2008-06-05
DE122008000048I1 (de)	2009-01-02
IS2276B (is)	2007-09-15
NO316176B1 (no)	2003-12-22
PT1047694E (pt)	2004-11-30
IL137041A0 (en)	2001-06-14
NO2008017I1 (no)	2008-12-01
GEP20022678B (en)	2002-04-25
BG64825B1 (bg)	2006-05-31
EP1047694B1 (en)	2004-07-07
EP1460072A1 (en)	2004-09-22
JP2002326990A (ja)	2002-11-15
PT1460072E (pt)	2006-07-31
ES2221354T3 (es)	2004-12-16
AU749549B2 (en)	2002-06-27
HUP0100941A3 (en)	2002-09-30
HK1031883A1 (en)	2001-06-29
NO20003561L (no)	2000-09-11
NZ505456A (en)	2003-06-30
NO2008017I2 (is)	2011-10-17
US20030176451A1 (en)	2003-09-18
CZ20002587A3 (en)	2001-05-16
JP3390741B2 (ja)	2003-03-31
AR015507A1 (es)	2001-05-02
DE69940128D1 (de)	2009-01-29
AP2000001861A0 (en)	2000-09-30
HRP20060387A2 (en)	2008-02-29
TW477788B (en)	2002-03-01
ATE270670T1 (de)	2004-07-15
CA2317589C (en)	2007-08-07

Publication	Publication Date	Title
SK285405B6 (sk)	2007-01-04	Bicyklické heteroaromatické zlúčeniny, spôsob ichprípravy, farmaceutický prostriedok s ich obsahoma ich použitie
US7157466B2 (en)	2007-01-02	Quinazoline ditosylate salt compounds
GB2345486A (en)	2000-07-12	Heteroaromatic protein tyrosine kinase inhibitors
CZ8799A3 (cs)	1999-06-16	Bicyklické heteroaromatické sloučeniny, způsob jejich výroby a farmaceutický prostředek
MXPA00006824A (en)	2001-07-31	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
HK1031883B (en)	2005-03-04	Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

Legal Events

Date	Code	Title	Description
2013-11-04	TE4A	Change of owner's address	Owner name: GLAXO GROUP LIMITED, BRENTFORD, MIDDLESEX, GB Effective date: 20130911
2014-04-01	SPCT	Transfer of rights of an spc	Owner name: GLAXOSMITHKLINE LLC; US Free format text: PRODUCT NAME: LAPATINIB; REGISTRATION NO/DATE: EU/1/07/440/001-002 20080610; FORMER OWNER: GLAXO GROUP LIMITED; GB Spc suppl protection certif: DO 73; 5005-2008 Effective date: 20150313
2015-04-01	PC4A	Assignment and transfer of rights	Owner name: GLAXOSMITHKLINE LLC, CORPORATION SERVICE COMPA, US Free format text: FORMER OWNER: GLAXO GROUP LIMITED, BRENTFORD, MIDDLESEX TW8 9GS, GB Effective date: 20150304
2016-06-01	PC4A	Assignment and transfer of rights	Owner name: LEO OSPREY LIMITED, BRENTFORD, MIDDLESEX,, GB Free format text: FORMER OWNER: GLAXOSMITHKLINE LLC, CORPORATION SERVICE COMPANY, WILMINGTON, DELAWARE, US Effective date: 20150917 Owner name: NOVARTIS AG, BASEL, CH Free format text: FORMER OWNER: LEO OSPREY LIMITED, BRENTFORD, MIDDLESEX, GB Effective date: 20150917
2016-06-01	SPCT	Transfer of rights of an spc	Owner name: LEO OSPREY LTD, GB Free format text: FORMER OWNER: GLAXOSMITHKLINE LLC; US Spc suppl protection certif: DO 73; 5005-2008 Effective date: 20160525 Owner name: NOVARTIS AG, CH Free format text: FORMER OWNER: LEO OSPREY LTD, GB Spc suppl protection certif: DO 73; 5005-2008 Effective date: 20160525
2017-05-03	SPCM	Change of validity term of an spc as amended by art. 17 (2) of ec reg. no. 1610/96 and art. 18 of ec reg. no. 469/2009	Free format text: PRODUCT NAME: LAPATINIB; FIRST REGISTRATION NO/DATE: EU/1/07/440/001, EU/1/07/440/002, 20080610, Spc suppl protection certif: 73 5005-2008 Filing date: 20081008 Extension date: 20230612
2019-03-01	MK4A	Patent expired	Expiry date: 20190108